CROSS-REFERENCE TO A RELATED APPLICATION
-
This application claims the benefit of U.S. Provisional Application Ser. No. 60/547,871, filed Feb. 25, 2004, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
-
In the last decade, scientists have labored to complete a high-quality, comprehensive sequence of the human genome. With its recent completion, a large number of genomic data sets have been made available in public databases. The available data, however, does not provide explanations regarding which aspects of human biology affect which genes. Researchers are just beginning to explore genomic function.
-
Several technological advances have made it possible to accurately measure cellular constituents and therefore derive profiles. For example, new techniques provide the ability to monitor the expression level of a large number of transcripts at any one time (see, for example, Schena et al., “Quantitative monitoring of gene expression patterns with a complementary DNA micro-array,” Science, 270:467-470 (1995); Lockhart et al., “Expression monitoring by hybridization to high-density oligonucleotide arrays,” Nature Biotechnology, 14:1675-1680 (1996); and Blanchard et al., “Sequence to array: Probing the genome's secrets,” Nature Biotechnology, 14:1649 (1996)). In organisms for which the complete genome is known, it is possible to analyze the transcripts of all genes within the cell. With other organisms, such as humans, for which there is an increasing knowledge regarding the genome, it is possible to simultaneously monitor large numbers of the genes within the cell.
-
One aspect of human biology/genomic function that is of great interest to the medical research community is cancer. Currently, genetic samples have been taken from patients having various stages of various types of cancer. Such samples have provided an extensive genetic data collection. To provide a system of organization, such genetic data are collected in DNA microarrays, which are sometimes commonly referred to as biochips, DNA chips, gene arrays, gene chips, and genome chips.
-
DNA microarrays exploit a phenomenon known as base-pairing or hybridization. To form the array, genetic samples are arranged in an orderly manner (typically in a rectangular grid) on a substrate. Examples of commonly used substrates include microplates and blotting membranes. Many modern microarrays include an array of oligonucleotide or peptide nucleic acid (PNA) probes, and the array is synthesized either in situ (on-chip) or by conventional synthesis followed by on-chip immobilization. The array on the chip is exposed to labeled sample DNA, hybridized, and the identity/abundance of complementary sequences are determined.
-
There are two major uses of DNA microarray technology. The first involves identification of the gene sequence. The second involves determination of expression level of genes, generally referred to as the abundance of the genes. In particular, expression or abundance of a gene is a measure of a relative level of activity of the gene in replication or translation in the presence of the probe. By analyzing the abundance of various genes in people of various conditions, a relationship between the genetic state of a person, in terms of relative levels of activity of various genes of that person, and that person's condition is assessed. To conduct such analysis, such arrays of expression levels include metadata describing characteristics of the people whose genetic material is sampled and additional metadata which identifies specific genes whose expression levels are represented in such arrays.
-
The use of microarrays are already being used for a number of beneficial purposes including, for example, identifying biomarkers of cancer (Welsh, J B et al., “Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum,” PNAS, 100(6):3410-3415 (March 2003)), creating gene expression-based classifications of cancers (Alzadeh, A A et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, 403:513-11 (2000); and Garber, M E et al., “Diversity of gene expression in adenocarcinoma of the lung,” Proc Natl Acad Sci USA, 98:13784-9 (2001)), and in drug discovery (Marton, M J et al., “Drug target validation and identification of secondary drug target effects using Microarrays,” Nat Med, 4(11):1293-301 (1998); and Gray, N S et al., “Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors,” Science, 281:533-538 (1998)). One tool that has been applied to microarrays to decipher and compare genome expression patterns in biological systems is Significance Analysis of Microarrays, or SAM (Tusher, V. et al., “Significance analysis of microarrays applied to ionizing radiation response,” Proceedings of the National Academy of Sciences, 2001. First published Apr. 17, 2001, 10.1073/pnas.091062498). This statistical method was developed as a cluster tool for use in identifying genes with statistically significant changes in expression. SAM has been used for a variety of purposes, including identifying potential drugs that would be effective in treating various conditions associated with specific gene expressions (Bunney W E, et al., “Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders,” Am J Psychiatry, 160(4):657-66 (April 2003)).
-
The known SVM or (Support Vector Machine) (as described in Michael P. et al., “Knowledge-based analysis of microarray gene expression data by using support vector machines,” Proceedings of the National Academy of Sciences, 97(1):262-67 (2000)) is a correlation tool shown to perform well in multiple areas of biological analysis, including evaluating microarray expression data (Brown et al, “Knowledge-based analysis of microarray gene expression data by using support vector machines,” Proc Natl Acad Sci USA, 97:262-267 (2000)), detecting remote protein homologies (Jaakkola, T. et al., “Using the Fisher kernel method to detect remote protein homologies,” Proceedings of the 7th International Conference on Intelligent Systems for Molecular Biology, AAAI Press, Menlo Park, Calif. (1999)), and recognizing translation initiation sites (Zien, A. et al., “Engineering support vector machine kernels that recognize translation initiation sites,” Bioinformatics, 16(9):799-807 (2000)). When used for classification, SVMs separate a given set of binary labeled training data with a hyper-plane that is maximally distant from set of data (the “maximal margin hyper-plane”). Where no linear separation is possible, SVMs utilize the technique of “kernels” to automatically realize a non-linear mapping to a feature space (Furey, T. S. et al., “Support vector machine classification and validation of cancer tissue samples using microarray expression data,” Bioinformatics, 16(10):906-914 (2000)).
-
Ranked as the third most commonly diagnosed cancer and the second leading cause of cancer deaths in the United States (American Cancer Society, “Cancer facts and figures,” Washington, D.C.: American Cancer Society (2000)), colon cancer is a deadly disease afflicting nearly 130,000 new patients yearly in the United States. Colon cancer is the only cancer that occurs with approximately equal frequency in men and women. There are several potential risk factors for the development of colon and/or rectal cancer. Known factors for the disease include older age, excessive alcohol consumption, sedentary lifestyle (Reddy, B. S., “Dietary fat and its relationship to large bowel cancer,” Cancer Res., 41:3700-3705 (1981)), and genetic predisposition (Potter, J D “Colorectal cancer: molecules and populations,” J Natl Cancer Institute, 91:916-932 (1999)).
-
Several molecular pathways have been linked to the development of colon cancer (see, for example, Leeman M F, et al., “New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression,” J Pathol., 201(4):528-34 (2003); Kanazawa, T et al., “Does early polypoid colorectal cancer with depression have a pathway other than adenoma-carcinoma sequence?,” Tumori., 89(4):408-11 (2003); and Notarnicola, M. et al., “Genetic and biochemical changes in colorectal carcinoma in relation to morphologic characteristics,” Oncol Rep., 10(6):1987-91 (2003)), and the expression of key genes in any of these pathways may be affected by inherited or acquired mutation or by hypermethylation. A great deal of research has been performed with regard to identifying genes for which changes in expression may provide an early indicator of colon cancer or a predisposition for the development of colon cancer. Unfortunately, no research has yet been conducted on identifying specific genes associated with colorectal cancer and specific outcomes to provide an accurate prediction of prognosis.
-
Survival of patients with colon and/or rectal cancer depends to a large extent on the stage of the disease at diagnosis. Devised nearly seventy years ago, the modified Dukes' staging system for colon cancer, discriminates four stages (A, B, C, and D), primarily based on clinicopathologic features such as the presence or absence of lymph node or distant metastases. Specifically, colonic tumors are classified by four Dukes' stages: A, tumor within the intestinal mucosa; B, tumor into muscularis mucosa; C, metastasis to lymph nodes and D, metastasis to other tissues. Of the systems available, the Dukes' staging system, based on the pathological spread of disease through the bowel wall, to lymph nodes, and to distant organ sites such as the liver, has remained the most popular. Despite providing only a relative estimate for cure for any individual patient, the Dukes' staging system remains the standard for predicting colon cancer prognosis, and is the primary means for directing adjuvant therapy.
-
The Dukes' staging system, however, has only been found useful in predicting the behaviour of a population of patients, rather than an individual. For this reason, any patient with a Dukes A, B, or C lesion would be predicted to be alive at 36 months while a patient staged as Dukes D would be predicted to be dead. Unfortunately, application of this staging system results in the potential over-treatment or under-treatment of a significant number of patients. Further, Dukes' staging can only be applied after complete surgical resection rather than after a pre-surgical biopsy.
-
Microarray technology, as described above, has permitted development of multi-organ cancer classifiers (Giordano, T. J. et al., “Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles,” Am J Pathol, 159:1231-8 (2001); Ramaswamy, S. et al., “Multiclass cancer diagnosis using tumor gene expression signatures,” Proc Natl Acad Sci USA, 98:15149-54 (2001); and Su, A. I. et al., “Molecular classification of human carcinomas by use of gene expression signatures,” Cancer Res, 61:7388-93 (2001)), identification of tumor subclasses (Dyrskjot, L. et al., “Identifying distinct classes of bladder carcinoma using microarrays,” Nat Genet, 33:90-6 (2003); Bhattacharjee, A. et al., “Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses,” Proc Natl Acad Sci USA, 98:13790-5 (2001); Garber, M. E. et al., “Diversity of gene expression in adenocarcinoma of the lung,” Proc Natl Acad Sci USA, 98:13784-9. (2001); and Sorlie, T. et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proc Natl Acad Sci USA, 98:10869-74 (2001)), discovery of progression markers (Sanchez-Carbayo, M. et al., “Gene Discovery in Bladder Cancer Progression using cDNA Microarrays,” Am J Pathol, 163:505-16 (2003); and Frederiksen, C M, et al., “Classification of Dukes' B and C colorectal cancers using expression arrays,” J Cancer Res Clin Oncol, 129:263-71 (2003)); and prediction of disease outcome (Henshall, S M et al., “Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse,” Cancer Res, 63:4196-203 (2003); Shipp, M A et al., “Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning,” Nat Med, 8:68-74 (2002); Beer, D G et al., “Gene-expression profiles predict survival of patients with lung adenocarcinoma,” Nat Med, 8:816-24 (2002); Pomeroy, S L et al., “Prediction of central nervous system embryonal tumor outcome based on gene expression,” Nature, 415:436-42 (2002); van 't Veer, L J et al., “Gene expression profiling predicts clinical outcome of breast cancer: Nature, 415:530-6. (2002); Vasselli, J R et al., “Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor,” Proc Natl Acad Sci USA, 100:6958-63 (2003); and Takahashi, M. et al., “Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification,” Proc Natl Acad Sci USA, 98:9754-9 (2001)) in many types of cancer.
-
Classification of patient prognosis by microarray analysis has promise in predicting the long-term outcome of any one individual based on the gene expression profile of the tumor at diagnosis. Inherent to this approach is the hypothesis that every tumor contains informative gene expression signatures, at the time of diagnosis, which can direct the biological behaviour of the tumor over time. To date, however, little success has been achieved in developing a classifier that will predict colon cancer outcome equivalent to or better than that which is possible using the standard clinicopathologic staging systems (i.e., Dukes' stage system). What is needed is a particularly effective mechanism for analyzing genomic array data to provide a classifier that accurately predicts cancer outcomes, in particular, colon cancer outcomes.
BRIEF SUMMARY OF THE INVENTION
-
The present invention provides systems and methods for predicting outcomes in patients diagnosed with cancer. Specifically, the subject invention utilizes molecular staging with gene expression profiles to stage patients with cancer. In a specific embodiment, the present invention provides a gene expression profile based classifier that provides a means for accurately predicting colon cancer outcome.
-
In accordance with an aspect of the invention, genes are classified according to degree of correlation with a clinical outcome for a cancer of interest (such as colon cancer). These genes are used to establish a set of reference gene expression levels (also referred to herein as a “classifier”). Biological information regarding the patient is received and used to extrapolate intracellular gene expression. The intracellular gene expression levels are compared to those in the classifier to predict clinical outcome.
-
In one embodiment of the invention, a method is provided in which the specific gene signatures for colon cancer are identified. To do so, frozen tumor specimens form patients with known outcomes are collected and frozen. The outcomes are linked to a specific core set of genes that are weighted in importance by (1) selecting genes of interest by applying microarray analysis; (2) producing a classifier using support vector machines (SVM); and (3) cross-validating the genes of interest and the classifier by comparing them against an independent set of test data. In a preferred embodiment, significance analysis of microarrays (SAM) is utilized to select genes of interest.
-
Genome wide microarray analyses can produce large datasets that can be pattern-matched to clinicopathologic parameters such as patient outcomes and prognosis. Accordingly, the subject invention identifies gene expression signatures that would predict colon cancer outcome more accurately than the well-accepted Dukes' staging system.
-
In one embodiment, a group of colon cancer patients was examined to develop a survival classifier, which was subsequently validated using an entirely independent test set of data derived on a different microarray platform at a different performance site. The classifier of the subject invention was ultimately based on a core set of genes selected for their correlation to survival. A number of the genes in the core set demonstrated intrinsic biological significance for colon cancer progression.
-
With the ability to predict cancer outcomes/prognosis using the subject invention, appropriate treatment protocols can be selected for patients. For example, patients assessed using the subject invention and identified to have poor outcomes may be treated more aggressively or with specific agents (i.e., anti-sense agents, RNA inhibition agents, small molecule inhibitors of the cancer activity, gene therapy, etc.). Accordingly, an important contribution of the prognosis/survival classifier of the present invention is the ability to identify those Dukes' stage B and C cases for which chemotherapy may be beneficial.
DESCRIPTION OF THE FIGURES
-
The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.
-
FIG. 1A is a heatmap illustrating cluster analysis of genes selected in accordance with the present invention when correlated with prognosis/patient survival.
-
FIG. 1B is a heatmap illustrating cluster analysis of genes selected in accordance with the present invention when grouped by Dukes' stage B and C.
-
FIG. 2A graphically illustrates a Kaplan-Meier survival curve based on gene expression profiling in accordance with the present invention.
-
FIG. 2B graphically illustrates a Kaplan-Meier survival curve based on Dukes' staging.
-
FIGS. 3A-3C illustrate survival curves for molecular classifiers in accordance with the subject invention.
DETAILED DISCLOSURE OF THE INVENTION
-
The present invention provides systems and methods for predicting cancer prognosis and outcomes. Specifically, the subject invention utilizes molecular staging with gene expression profiles to stage patients with cancer. In a specific embodiment, the present invention provides a gene expression profile based classifier for predicting cancer outcomes/prognosis. Both microarray analysis and binary classification are used to create the classifier of the invention.
-
The subject invention provides methods for predicting patient outcomes comprising: identifying genes that correlate with a clinical outcome for a cancer of interest (such as colon cancer); establishing a set of reference gene expression levels (also referred to herein as a “classifier”) for said identified genes; receiving biological information regarding the patient; using the biological information to extrapolate intracellular gene expression; and comparing intracellular gene expression levels to those in the classifier to predict clinical outcome.
-
Biological information of the invention includes, but is not limited to, clinical samples of bodily fluids or tissues; DNA profile information; and RNA profile information. Methods for preparing clinical samples for gene expression analysis are well known in the art, and can be carried out using commercially available kits.
-
In one embodiment, the subject invention provides methods for predicting colon cancer patient outcomes using a SAM selected set of genes derived from a genome wide analysis of gene expression. Those patients with good and bad prognoses are first clustered into groups that suggest outcome-rich information that is likely present in the gene expression dataset. Subsequently, a supervised SVM analysis identifies a core set of genes that appears in a majority (i.e., 50% or greater, including for example, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the cross validation folds and accurately predicts colon cancer survival. Preferably, a core set of genes that appears in 75% of the cross validation folds is identified by an SVM to be used in predicting colon cancer survival.
-
In one embodiment, a gene core set is derived from a cDNA microarray that includes both named and unnamed genes. The resultant gene set is highly accurate in predicting cancer survival when compared with Dukes staging data from the same patients. To validate a cDNA-based classifier of the subject invention, a normalized and scaled oligonucleotide-based cancer database is evaluated against a completely independent set of test data derived from a different microarray platform.
-
Accordingly, the subject invention provides a system for predicting clinical outcome in a patient diagnosed with cancer, wherein the system is useful in offering support/advice in making treatment decisions. The system comprises (1) a data storage device for collecting data (i.e., gene data); and (3) a computing means for receiving and analyzing data to accurately determine genes associated with poor or good patient prognosis. A graphical user interface can be included with the systems of the invention to display clinical data as well as enable user-interaction.
-
In one embodiment, the system of the invention further includes an intelligence system that can use the analyzed clinical data to classify gene samples and offer support/advice for making clinical decisions (i.e., to interpret predicted clinical outcome and provide appropriate treatment). An intelligence system of the subject invention can include, but is not limited to, artificial neural networks, fuzzy logic, evolutionary computation, knowledge-based systems, and artificial intelligence.
-
In accordance with the subject invention, the computing means is preferably a digital signal processor, which can automatically and accurately analyze gene data and determine those genes that strongly correlate to clinical outcome.
-
In one embodiment, the system of the subject invention is stationary. For example, the system of the invention can be used within a healthcare setting (i.e., hospital, physician's office).
-
Definitions
-
As used herein, the term “patient” refers to humans as well as non-human animals including, and not limited to, mammals, birds, reptiles, amphibians, and fish. Preferred non-human animals include mammals (i.e., mouse, rat, rabbit, monkey, dog, cat, primate, pig). A patient may also include transgenic animals. In certain embodiments, a patient may be a laboratory animal raised by humans in a controlled environment other than its natural habitat.
-
The term “cancer,” as used herein, refers to a malignant tumor (i.e., colon or prostate cancer) or growth of cells (i.e., leukaemia). Cancers tend to be less differentiated than benign tumors, grow more rapidly, show infiltration, invasion, and destruction, and may metastasize. Cancer include, and are not limited to, colon and rectal cancers, fibrosarcoma, myxosarcoma, antiosarcoma, leukaemia, squamous cell carcinoma, basal cell carcinoma, malignant melanoma, renal cell carcinoma, and hepatocellular carcinoma.
-
A “marker gene,” as used herein, refers to any gene or gene product (i.e., protein, peptide, mRNA) that indicates a particular clinicopathological state (i.e., carcinoma, normal dysplasia and outcomes) or indicates a particular cell type, tissue type, or origin. The expression or lack of expression of a marker gene may indicate a particular physiological and/or diseased state of a patient, organ, tissue, or cell. Preferably, the expression or lack of expression may be determined using standard techniques such as RT-PCR, sequencing, immunochemistry, gene chip analysis, etc. In certain particular embodiments, the level of expression of a marker gene is quantifiable.
-
The term “polynucleotide” or “oligonucleotide,” as used herein, refers to a polymer of nucleotides. Typically, a polynucleotide comprises at least three nucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (i.e., 2-aminoadensoine, 2-thio-thymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-methylcytidine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (i.e., methylated bases), intercalated bases, modified sugars (i.e., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose), or modified phosphate groups (i.e., phosphorothioates and 5′-N-phosphoramidite linkages).
-
As used herein, the term “tumor” refers to an abnormal growth of cells. The growth of the cells of a tumor typically exceeds the growth of normal tissue and tends to be uncoordinated. The tumor may be benign (i.e., lipoma, fibroma, myxoma, lymphangioma, meningioma, nevus, adenoma, leiomyoma, mature teratoma, etc.) or malignant (i.e., malignant melanoma, ovarian cancer, carcinoma in situ, carcinoma, adenocarcinoma, liposarcoma, mesothelioma, squamous cell carcinoma, basal cell carcinoma, colon cancer, lung cancer, etc.).
-
The term “bodily fluid,” as used herein, refers to a mixture of molecules obtained from a patient. Bodily fluids include, but are not limited to, exhaled breath, whole blood, blood plasma, urine, semen, saliva, lymph fluid, meningal fluid, amniotic fluid, glandular fluid, sputum, feces, sweat, mucous, and cerebrospinal fluid. Bodily fluid also includes experimentally separated fractions of all of the preceding solutions or mixtures containing homogenized solid material, such as feces, tissues, and biopsy samples.
-
Computing Means
-
Correlating genes to clinical outcomes in accordance with the subject invention can be performed using software on a computing means. The computing means can also be responsible for maintenance of acquired data as well as the maintenance of the classifier system itself. The computing means can also detect and act upon user input via user interface means known to the skilled artisan (i.e., keyboard, interactive graphical monitors) for entering data to the computing system.
-
In one embodiment, the computing means further comprises means for storing and means for outputting processed data. The computing means includes any digital instrumentation capable of processing data input from the user. Such digital instrumentation, as understood by the skilled artisan, can process communicated data by applying algorithm and filter operations of the subject invention. Preferably, the digital instrumentation is a microprocessor, a personal desktop computer, a laptop, and/or a portable palm device. The computing means can be general purpose or application specific.
-
The subject invention can be practiced in a variety of situations. The computing means can directly or remotely connect to a central office or health care center. In one embodiment, the subject invention is practiced directly in an office or hospital. In another embodiment, the subject invention is practiced in a remote setting, for example, personal residences, mobile clinics, vessels at sea, rural villages and towns without direct access to healthcare, and ambulances, wherein the patient is located some distance from the physician.
-
In a related embodiment, the computing means is a custom, portable design and can be carried or attached to the health care provider in a manner similar to other portable electronic devices such as a portable radio pr computer.
-
The computing means used in accordance with the subject invention can contain at least one user-interface device including, but not limited to, a keyboard, stylus, microphone, mouse, speaker, monitor, and printer. Additional user-interface devices contemplated herein include touch screens, strip recorders, joysticks, and rollerballs.
-
Preferably, the computing means comprises a central processing unit (CPU) having sufficient processing power to perform algorithm operations in accordance with the subject invention. The algorithm operations, including the microarray analysis operations (such as SAM or binary classification), can be embodied in the form of computer processor usable media, such as floppy diskettes, CD-ROMS, zip drives, non-volatile memory, or any other computer-readable storage medium, wherein the computer program code is loaded into and executed by the computing means. Optionally, the operational algorithms of the subject invention can be programmed directly onto the CPU using any appropriate programming language, preferably using the C programming language.
-
In certain embodiments, the computing means comprises a memory capacity sufficiently large to perform algorithm operations in accordance with the subject invention. The memory capacity of the invention can support loading a computer program code via a computer-readable storage media, wherein the program contains the source code to perform the operational algorithms of the subject invention. Optionally, the memory capacity can support directly programming the CPU to perform the operational algorithms of the subject invention. A standard bus configuration can transmit data between the CPU, memory, ports and any communication devices.
-
In addition, as understood by the skilled artisan, the memory capacity of the computing means can be expanded with additional hardware and with saving data directly onto external mediums including, for example, without limitation, floppy diskettes, zip drives, non-volatile memory and CD-ROMs.
-
Further, the computing means can also include the necessary software and hardware to receive, route and transfer data to a remote location.
-
In one embodiment, the patient is hospitalized, and clinical data generated by a computing means is transmitted to a central location, for example, a monitoring station or to a specialized physician located in a different locale.
-
In another embodiment, the patient is in remote communication with the health care provider. For example, patients can be located at personal residences, mobile clinics, vessels at sea, rural villages and towns without direct access to healthcare, and ambulances, and by using the classifier system of the invention, still provide clinical data to the health care provider. Advantageously, mobile stations, such as ambulances, and mobile clinics, can monitor patient health by using a portable computing means of the subject invention when transporting and/or treating a patient.
-
To ensure patient privacy, security measures, such as encryption software and firewalls, can be employed. Optionally, clinical data can be transmitted as unprocessed or “raw” signal(s) and/or as processed signal(s). Advantageously, transmitting raw signals allows any software upgrades to occur at the remote location where a computing means is located. In addition, both historical clinical data and real-time clinical data can be transmitted.
-
Communication devices such as wireless interfaces, cable modems, satellite links, microwave relays, and traditional telephonic modems can transfer clinical data from a computing means to a healthcare provider via a network. Networks available for transmission of clinical data include, but are not limited to, local area networks, intranets and the open internet. A browser interface, for example, NETSCAPE NAVIGATOR or INTERNET EXPLORER, can be incorporated into communications software to view the transmitted data.
-
Advantageously, a browser or network interface is incorporated into the processing device to allow the user to view the processed data in a graphical user interface device, for example, a monitor. The results of algorithm operations of the subject invention can be displayed in the form of interactive graphics.
-
Dukes' Staging as a Classifier
-
Since Dukes' staging describes the survival of a population of patients, rather than an individual, any individual patient can be classified as alive or dead using the survivorship of the population to predict that of the individual. In other words, if the survival of a Dukes C population is 55% at 36 months of follow up, the Dukes C individual patient would be classified as alive at 36 months but with only a 55% accuracy rate. By making these assumptions, the accuracy of a staging by a microarray classifier of the subject invention to that of a clinical staging system can be compared.
-
Identification of Prognosis-Related Genes
-
As a first step in the survival analysis of microarray data, genes that best separate cancer patients with poor and good prognosis were identified. Censored-survival analysis using significance analysis of microarrays (SAM) or any other microarray analysis (i.e., clustering methods such as those disclosed by Eisen et al., “Cluster analysis and display of genome-wide expression patterns,” Proc. Natl. Acad. Sci. USA, 95:14863-14868 (1998); Alon et al., “Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays,” Proc. Natl. Acad. Sci. USA, 96:6745-6750 (1999); and Ben-Dor et al., “Tissue classification with gene expression profiles,” J. Comput. Biol., 7:559-583 (2000); classification trees such those disclosed by Dubitzky et al., “A database system for comparative genomic hybridization analysis,” IEEE Eng Med Biol Mag, 20(4):75-83 (2001); genetic algorithms such as those disclosed by L1 et al., “Computational analysis of leukemia microarray expression data using the GA/KNN,” in Methods of Microarray Data Analysis, Kluwer Academic Publishers (2001); neural networks such as those disclosed by Hwang et al., “Applying machine learning techniques to analysis of gene expression data: cancer diagnosis,” in Methods of Microarray Data Analysis, Kluwer Academic Publishers (2001); and the “Neighborhood Analysis” (a weighted correlation method) as disclosed by Golub et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring,” Science, 286:531-537 (1999)) can be used to select genes correlated with prognosis in accordance with the subject invention.
-
Using SAM or any other microarray analysis, genes can be selected that most closely correlate with selected survival times. Permutation analysis can then used to estimate the false discovery rate (FDR). The resultant mean-centered gene expression vectors can then be clustered and visualized using known computer software (i.e., Cluster 3.0 and Java TreeView 1.03, both of which are provided by Hoon MJLd, et al., “Open Source Clustering Software,” Bioinformatics 2003, in press).
-
Classifier Construction and Evaluation
-
According to the present invention, a gene classifier can be constructed to predict a set time of outcome among a set number of patients using microarray data produced on a cDNA platform. In one embodiment, the classifier of the subject invention is produced on a computing means that using SAM two-class gene selection and a support vector machine classification. In one embodiment, the SAM procedure is empirically set to select enough genes to satisfy a set FDR. Such selected genes can then be used in a linear support vector machine to classify the samples as having poor or good prognosis.
-
Leave-one-out cross-validation (LOOCV) operation can also be utilized to construct a classifier (i.e., neural network-based classifier) as well as to estimate the prediction accuracy of the classifier of the subject invention. In one embodiment, the classification process includes both gene selection and SVM classification creation; therefore, both steps can be performed on each training set after the test example is removed. According to the subject invention, samples can be classified as having “good” or “poor” prognosis based on survival for a certain set amount of time. In a preferred embodiment, “good” or “poor” prognosis is based on more or less than 36 months, respectively.
-
By using the leave-one-out cross validation approach, the subject invention provides a means for ranking the genes selected. The number of times a particular gene is chosen can be an indicator of the usefulness of that gene for general classification and may imply biological significance.
-
In a preferred embodiment, the classifier of the subject invention is prepared by (1) SAM gene selection using a t-test and (2) classification using a neural network. The classifier is prepared after a test sample is left out (from the LOOCV) to avoid bias from the gene selection step. Since the classification problem is a binary decision, a t-test was used for gene selection.
-
Preferably, once a gene set is selected, a feed-forward back-propogation neural network system (see Rumelhart, D. E. and J. L. McClelland, “Parallel Distributed Processing: Exploration in the Microstructure of Cognition,” Cambridge, Mass.: MIT Press (1986); and Fahlman, S. E., “Faster-Learning Variations on Back-Propogation: An Empirical Study,” Proceedings of the 1988 Connectionist Models Summer School, Los Altos, Calif.: Morgan-Kaufmann (1988)) is used. In one embodiment, a feed-forward back-propogation neural network with a single layer of 10 units is used. Neural network systems are extremely robust to both the number of genes selected and the level of noise in these genes.
-
Statistical Significance
-
Differences between Kaplan-Meier curves can be evaluated using the log-rank test, which is well known to the skilled statistician. This can be performed both for the initial survival analysis and for the classifier results. In accordance with the present invention, the classifier can split the samples into various groups (i.e., two groups: those predicted as good or poor prognosis). Classifier accuracy can be reported to the user both as overall accuracy and as specificity/sensitivity. In one embodiment, a McNemar's Chi-Squared test is used to compare the molecular classifier with the use of a Dukes' staging classifier. In a related embodiment, several permutations of the dataset (i.e., 1,000 permutations) are used to measure the significance of the classifier results as compared to chance.
EXAMPLE 1
Human Colon Cancer Survival Classifier
-
Training Set Tumor Samples
-
In one embodiment of the subject invention, a colon cancer survival classifier was developed using 78 tumor samples, including 3 adenomas and 75 cancers. Informative frozen colorectal cancer samples were selected from the Moffitt Cancer Center Tumor Bank (Tampa, Fla.) based on evidence for good (survival >36 mo) or poor prognosis (survival <36 mo) from the Tumor Registry. Dukes' stages can include B, C, and D. In this particular embodiment, survival was measured as last contact minus collection date for living patients, or date of death minus collection date for patients who have died.
-
In this embodiment, the number of samples per Dukes' stage was as follows: 23 patients with stage B, 22 patients with stage C and 30 patients with stage D disease. Just as adenomas can be included to help train the classifier to recognize good prognosis patients, Dukes D patients with synchronous metastatic disease can be used to train the classifier to recognize poor prognosis patients.
-
In a related embodiment, all samples were selected to have at least 36 months of follow-up. The follow-up results in this embodiment showed that thirty-two of the patients survived more than 36 months, while 46 patients died within 36 months. With this particular embodiment, the median follow-up time for all 78 patients was 27.9 months. The median follow-up for the poor prognosis cases (<36 months survival) was 11.7 months and for the good prognosis cases (>36 months survival) it was 64.2 months.
-
Since the NIH consensus conference in 1990, chemotherapeutic application in the United States has been relatively homogeneous, with nearly all Dukes stage B avoiding chemotherapy, and nearly all Dukes stage C receiving 6 months of adjuvant 5-fluorouracil (5-FU) and leucovorin.
-
Test Set Tumor Samples (Denmark)
-
In another embodiment, eighty-eight patients with Dukes' stage B and C colorectal cancer and a minimum follow-up time of 60 months were selected for array hybridization. Ten micrograms of total RNA were used as starting material for the cDNA preparation and hybridized to Affymetrix U133A GeneChips (Santa Clara, Calif.) by standard protocols supplied by the manufacturer. The U133A gene chip is disclosed in U.S. Pat. Nos. 5,445,934; 5,700,637; 5,744,305; 5,945,334; 6,054,270; 6,140,044; 6,261,776; 6,291,183; 6,346,413; 6,399,365; 6,420,169; 6,551,817; 6,610,482; and 6,733,977; and in European Patent Nos. 619,321 and 373,203, all of which are hereby incorporated in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
-
With this particular embodiment, there were 28 patients with stage B and 60 patients with stage C colorectal cancers. All Dukes' stage B patients were treated by surgical resection alone whereas all C patients received 5-FU/leucovorin adjuvant chemotherapy in addition to surgery. Colorectal tumor samples were obtained fresh from surgery and were immediately snap-frozen in fluid nitrogen but were not microdissected, with the potential for inclusion of samples with <80% purity. Total RNA was isolated from 50-150 mg tumor sample using RNAzol (WAK-Chemie Medical) or using spin column technology (Sigma) according to the manufacturer's instructions. Results were noted (i.e., fifty-seven of the patients survived more than 36 months, while 31 died within 36 months).
-
32K cDNA Array Hybridization and Scanning
-
According to the subject invention, samples can be microdissected (>80% tumor cells) by frozen section guidance and RNA extraction performed using Trizol followed by secondary purification on RNAEasy columns. The samples can then be profiled on cDNA arrays (i.e., TIGR's 32,488-element spotted cDNA arrays, containing 31,872 human cDNAs representing 30,849 distinct transcripts—23,936 unique TIGR TCs and 6,913 ESTs, 10 exogenous controls printed 36 times, and 4 negative controls printed 36-72 times).
-
In one embodiment, tumor samples are co-hybridized with a common reference pool in the Cy5 channel for normalization purposes. cDNA synthesis, aminoallyl labeling and hybridizations can be performed according to previously published protocols (see Hegde, P. et al., “A concise guide to cDNA microarray analysis,” Biotechniques; 29:552-562 (2000) and Yang, I. V, et al., “Within the fold: assessing differential expression measures and reproducibility in microarray assays,” Genome Biol; 3:research0062 (2002)). For example, labeled first-strand cDNA is prepared, and co-hybridized with labeled samples are prepared, from a universal reference RNA consisting of equimolar quantities of total RNA derived from three cell lines, CaCO2 (colon), KM12L4A (colon), and U118MG (brain). Detailed protocols and description of the array are available at <http://cancer.tigr.org>. Array probes are identified and local background can be subtracted in Spotfinder (Saeed, A. I. et al., “TM4: a free, open-source system for microarray data management and analysis,” Biotechniques; 34:374-8 (2003)). Individual arrays can be normalized in MIDAS (see Saeed, A.I. ibid.) using LOWESS (an algorithm known to the skilled artisan for use in normalizing data) with smoothing parameter set to 0.33.
-
Microarray Hybridization and Scanning of Denmark Samples
-
The first and second strand cDNA synthesis can be performed using the SuperScript II System (Invitrogen) according to the manufacturer's instructions except using an oligodT primer containing a T7 RNA polymerase promoter site. Labeled cRNA is prepared using the BioArray High Yield RNA Transcript Labeling Kit (Enzo). Biotin labeled CTP and UTP (Enzo) are used in the reaction together with unlabeled NTP's. Following the IVT reaction, the unincorporated nucleotides are removed using RNeasy columns (Qiagen). Fifteen micrograms of cRNA are fragmented at 940 C for 35 min in a fragmentation buffer containing 40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc. Prior to hybridization, the fragmented cRNA in a 6×SSPE-T hybridization buffer (1 M NaCl, 10 mM Tris pH 7.6, 0.005% Triton) is heated to 95° C. for 5 min and subsequently to 45° C. for 5 min before loading onto the Affymetrix HG_U133A probe array cartridge. The probe array is then incubated for 16 h at 45° C. at constant rotation (60 rpm). The washing and staining procedure can be performed in an Affymetrix Fluidics Station.
-
The probe array can be exposed to several washes (i.e., 10 washes in 6×SSPE-T at 25° C. followed by 4 washes in 0.5×SSPE-T at 50° C.). The biotinylated cRNA can then be stained with a streptavidinphycoerythrin conjugate, final concentration 2 mg/ml (Molecular Probes, Eugene, Oreg.) in 6×SSPE-T for 30 min at 25° C. followed by 10 washes in 6×SSPE-T at 25° C. An antibody amplification step can then follow, using normal goat IgG as blocking reagent, final concentration 0.1 mg/ml (Sigma) and biotinylated anti-streptavidin antibody (goat), final concentration 3 mg/ml (Vector Laboratories). This can be followed by a staining step with a streptavidin-phycoerythrin conjugate, final concentration 2 mg/ml (Molecular Probes, Eugene, Oreg.) in 6×SSPE-T for 30 min at 25° C. and 10 washes in 6×SSPE-T at 25° C. The probe arrays are scanned (i.e., at 560 nm using a confocal laser-scanning microscope (Hewlett Packard GeneArray Scanner G2500A)). The readings from the quantitative scanning can then be analyzed by the Affymetrix Gene Expression Analysis Software (MAS 5.0) and normalized to a common mean expression value of 150.
-
Survival Analysis
-
The first analysis of the colon cancer survival data can be performed using censored survival time (in months) and 500 permutations. Significance analysis of microarrays (SAM) can then be used to select genes most closely correlated to survival. The subset of genes that correspond to an empirically derived, estimated false discovery rate (FDR) is then chosen. This subset of genes can then be used in subsequent analyses. In one embodiment, Cluster 3.0 and Java TreeView 1.03 are used to cluster and visualize the SAM-selected genes.
-
A hierarchical clustering algorithm can be chosen, with complete linkage and the correlation coefficient (i.e., Pearson correlation coefficient) as the similarity metric. In another embodiment, the Dukes' staging clusters are manually created in the appropriate format. Clustering software produces heatmap (see FIGS. 1A and 1B) and dendrograms. The highest level partition of the SAM-selected genes can then be chosen as a survival grouping. Given two clusters of survival times, Kaplan-Meier curves can be plotted (see FIGS. 2A and 2B).
-
Identification of Prognosis-Related Genes
-
According to the subject invention, SAM survival analysis can be used to identify a set of genes most correlated with censored survival time using the training set tumor samples. In one embodiment, a set of 53 genes was found, corresponding to a median expected false discovery rate (FDR) of 28%. These genes are listed in the following Table 1, wherein genes denoted with (+) indicate a positive correlation to survival time and genes without the (+) notation indicate a negative correlation in survival time (over expression in poor prognosis cases). Included in this list of genes in Table 1 are several genes believed to be biologically significant, such as osteopontin and neuregulin.
TABLE 1 |
|
|
Censored survival analysis using SAM, resultant 53 genes selected with median |
28% FDR |
| UniGene | |
GeneBank ID | ID | Description |
|
N36176 | Hs.108636 | membrane protein CH1 |
AA149253 | Hs.107987 | N/A |
AA425320 | Hs.250461 | hypothetical protein; MDG1; similar to putative microvascular |
| | endothelial differentiation gene 1; similar to X98993 (PID: g1771560) |
AA775616 | Hs.313 | OPN-b; osteopontin; secreted phosphoprotein 1 (osteopontin, bone |
| | sialoprotein I, early T-lymphocyte activation 1) |
N72847 | Hs.125221 | Alu subfamily SP sequence contamination warning entry. [Human] |
| | {Homo sapiens} |
AA706226 | Hs.113264 | neuregulin 2 isoform 4 |
AA976642 | Hs.42116 | axin 2 (conductin, axil) |
AA133215 | Hs.32989 | Receptor activity-modifying protein 1 precursor (CRLR activity- |
| | modifyingprotein 1) |
AA457267 | Hs.70669 | P19 protein; HMP19 protein |
N50073 | Hs.84926 | hypothetical protein |
R38360 | Hs.145567 | Unknown {Homo sapients} |
AA450205 | Hs.8146 | translocation protein-1; Sec62; Dtrp1 protein; membrane protein |
| | SEC62, S. cerevisiae, homolog of [Homo sapiens]; |
AA148578 | Hs.110956 | KOX 13 protein (56 AA) |
R38640 | Hs.89584 | insulinoma-associated 1; bA470C13.2 (insulinoma-associated protein 1) |
AA487274 | Hs.48950 | heptacellular carcinoma novel gene-3 protein; DAPPER1 |
N53172 | Hs.23016 | orphan receptor; orphan G protein-coupled receptor RDC1 |
AA045308 | Hs.7089 | insulin induced protein 2; INSIG-2 membrane protein |
AA045075 | Hs.62751 | syntaxin 7 |
N63366 | Hs.161488 | N/A |
R22340 | null | chr2 synaptotagmin; KIAA1228 protein |
AA437223 | Hs.46640 | Adult retina protein |
AA481250 | Hs.154138 | chitinase precursor; chitinase 3-like 2; chondrocyte protein 39 |
AA045793 | Hs.6790 | hypothetical protein; MDG1; similar to putative microvascular |
| | endothelial differentiation gene 1; similar to X98993 (PID: g1771560); |
| | microvascular endothelial differentiation gene 1 product; microvascular |
| | endothelial differentiation gene 1; DKFZP564F1862 p |
H87795 | Hs.233502 | N/A |
AA121806 | Hs.84564 | Rab3c; hypothetical protein BC013033 |
AA284172 | Hs.89385 | NPAT; predicted amino acids have three regions which share similarity |
| | to annotated domains of transcriptional factor oct-1, nucleolus- |
| | cytoplasm shuttle phosphoprotein and protein kinases; NPAT; nuclear |
| | protein, ataxiatelangiectasia locus; Similar to nuc |
R68106 | Hs.233450 | Fc-gamma-RIIb2; precursor polypeptide (AA −42 to 249); IgG Fc |
| | receptor; IgG Fc receptor; IgG Fc receptor beta-Fc-gamma-RII; IgG Fc |
| | fragment receptor precursor; Fc gamma RIIB [Homo sapiens]; Fc |
| | gamma RIIB [Ho |
AA479270 | Hs.250802 | Diff33 protein homolog; KIAA1253 protein [Homo sapiens]; |
| | KIAA1253protein [Homo sapiens] |
AA432030 | Hs.179972 | Interferon-induced protein 6-16 precursor (Ifi-6-16). [Human] {Homo |
| | sapiens} |
R10545 | Hs.148877 | dJ425C14.2 (Placental protein |
AA453508 | Hs.168075 | transportin; karyopherin (importin) beta 2 [Homo sapiens]; karyopherin |
| | beta 2; importin beta 2; transportin; M9 region interaction protein [Homo |
| | sapiens] |
AI149393 | Hs.9302 | phosducin-like protein; phosducin-like protein; phosducin-like protein; |
| | phosducin-like protein; hypothetical protein; phosducin-like; Unknown |
| | (proteinfor MGC: 14088) [Homo sapiens] |
AA883496 | Hs.125778 | Null |
AA167823 | Hs.112058 | CD27BP {Homo sapiens} |
AI203139 | Hs.180370 | hypothetical protein FLJ30934 [Homo sapiens] |
+H19822 | Hs.2450 | KIAA0028; leucyl-tRNA synthetase, mitochondrial [Homo sapiens]; |
| | leucyltRNA synthetase, mitochondrial [Homo sapiens]; leucine-tRNA |
| | ligase precursor; leucine translase [Homo sapiens] |
+W73732 | Hs.83634 | Null |
+AA777892 | Hs.121939 | Null |
+AA885478 | Hs.125741 | unnamed protein product [Homo sapiens]; hypothetical protein |
| | FLJ12505 [Homo sapiens]; Unknown (protein for MGC: 39884) [Homo |
| | sapiens] |
+AA932696 | Hs.8022 | TU3A protein; TU3A protein [Homo sapiens] |
+AA481507 | Hs.159492 | unnamed protein product [Homo sapiens] |
+H18953 | Hs.15232 | Null |
+AA709158 | Hs.42853 | put. DNA binding protein; put. DNA binding protein; cAMP responsive |
| | element binding protein-like 1; Creb-related protein [Homo sapiens] |
+AA488652 | Hs.4209 | HSPC235; ribosomal protein L2; Similar to ribosomal protein, |
| | mitochondrial, L2 [Homo sapiens]; mitochondrial ribosomal protein |
| | L37; ribosomal protein, mitochondrial, L2 [Homo sapiens] |
+N39584 | Hs.17404 | Null |
+H62801 | Hs.125059 | Unknown (protein for IMAGE: 4309224) [Homo sapiens]; hypothetical |
| | protein [Homo sapiens] |
+H17638 | Hs.17930 | dJ1033B10.2.2 (chromosome 6 open reading frame 11 (BING4), |
| | isoform 2) [Homo sapiens] |
+R43684 | Hs.165575 | dJ402G11.5 (novel protein similar to yeast and bacterial predicted |
| | proteins) {Homo sapiens} |
+N21630 | Hs.143039 | hypothetical protein PRO1942 |
+T81317 | Hs.189846 | Alu subfamily J sequence contamination warning entry. [Human] |
| | {Homosapiens} |
+R45595 | Hs.23892 | Null |
+T90789 | Hs.121586 | ray; small GTP binding protein RAB35 [Homo sapiens]; RAB35, |
| | member RAS oncogene family,; ras-related protein rab-1c (GTP-binding |
| | protein ray) [Homosapiens] |
+AA283062 | Hs.73986 | Similar to CDC-like kinase 2 {Homo sapiens} |
|
Any and all of the nucleotide and/or amino acid sequences associated with the accession numbers listed in Table 1 are hereby incorporated by reference. |
-
FIG. 1A presents a graphical representation of the 53 SAM-selected genes (as described above) as a clustered heat map. The red color represents over-expressed genes relative to green, under-expressed genes. FIG. 1A shows only the Dukes' stage B and C cases, whose outcome Dukes' staging predicts poorly. Since only genes correlated with survival are used in clustering, the distinctly illustrated clusters in the heatmap correspond to very different prognosis groups.
-
The 53 SAM-selected genes were also arranged by annotated Dukes' stage in FIG. 1B. Unlike FIG. 1A, where two gene groups were apparent, there was no discernible gene expression grouping when arranged by Dukes' stage.
-
FIG. 2A shows the Kaplan-Meier plot for two dominant clusters of genes correlated with stage B and C test set tumor samples. Clearly, these genes separated the cases into two distinct clusters of patients with good prognosis (cluster 2) and poor prognosis (cluster 1) (P<0.001 using a log rank test). FIG. 2B presents a Kaplan-Meier plot of the survival times of Dukes' stage B and C tumors grouped by stage, showing no statistically significant difference.
-
As illustrated in FIGS. 1A, 1B, 2A, and 2B, gene expression profiles separate good and poor prognosis cases better than Dukes' staging. This suggests that a gene-expression based classifier, as provided by the present invention, is more accurate at predicting patient prognosis than the traditional Dukes' staging.
-
Dukes' Staging as a Prognosis Classifier
-
As noted above, Dukes' staging provides only a probability of survival for each member of a population of patients, based on historical statistics. Accordingly, the prognosis of an individual patient can be predicted based on historical outcome probabilities of the associated Dukes' stage. For example, if a Dukes' C. survival rate was 55% at 36 months of follow up, any individual Dukes' C. patient would be classified as having a good prognosis since more than 50% of patients would be predicted to be alive.
-
Performance of a Colorectal Cancer Survival Classifier of the Present Invention as Compared to Dukes' Staging
-
In order to determine the value of the human colon cancer prognosis/survival classifier of the subject invention, a classifier of the invention was compared to the Dukes' clinical staging approach currently in widespread use. In an initial set of 78 tumors (from the test set tumor samples described above), a classifier (Classifier A) of the present invention predicted 100%, 69%, 55% and 20% for Adenomas, and Dukes' stages B, C and D cancers, respectively. The overall accuracy was 77% (63% sensitivity/97% specificity).
-
Using LOOCV, Classifier A was evaluated in predicting prognosis for each patient at 36 months follow-up as compared to Dukes' staging predictions. The results of LOOCV demonstrated that Classifier A of the subject invention was 90% accurate (93% sensitivity/84% specificity) in predicting the correct prognosis for each patient at 36 month of follow-up. A log-rank test of the two predicted groups (good and poor prognosis) was significant (P<0.001), demonstrating the ability of Classifier A to distinguish the two outcomes (FIG. 2A). Permutation analysis demonstrates the result is better than possible by chance (P<0.001-1000 permutations).
-
This result is also significantly higher than that observed using Dukes' staging as a classifier (77%) for the same group of patients (P=0.03878). The results for both Dukes' staging and molecular staging are summarized in Tables 2A-2C below. Shown first in Table 2A are the relative accuracies of Dukes' staging and the cDNA classifier (molecular staging) for all tumors and then a comparison by Dukes' stage. As shown in Table 2B, Dukes' staging was particularly bad at predicting outcome for patients with poor prognosis (70% and 55% for all stages and B and C, respectively). In contrast, molecular staging, as provided by the present invention, identified the good prognosis cases (the “default” classification using Dukes' staging), but also identified poor prognosis cases with a high degree of accuracy, Table 2C. Tables 2A-2C also show the detailed confusion matrix for all samples in the dataset, showing the equivalent misclassification rate of both good and poor prognosis groups by the classifier of the subject invention.
TABLE 2A |
|
|
LOOCV Accuracy of Dukes' vs. Molecular Staging for all |
tumors. |
Classification Method | Total Accuracy | Sensitivity | Specificity |
|
Dukes' Staging | 77% | 63% | 97% |
Molecular Staging | *90% | 93% | 84% |
|
-
TABLE 2B |
|
|
Comparison of Molecular Staging and Dukes' Staging |
Accuracy. |
|
Dukes' Stage |
Molecular Staging |
Dukes' Staging |
|
|
|
100% |
100% |
|
B |
87% |
70% |
|
C |
91% |
55% |
|
D |
90% |
97% |
|
|
-
TABLE 2C |
|
|
Confusion Matrix of cDNA Classifier Results. |
| Observed/Predicted | Poor | Good | Totals |
| |
| Poor | 43 | 3 | 46 |
| Good | 5 | 27 | 32 |
| Total | 48 | 30 | 78 |
| |
| *Dukes' staging vs. cDNA Classifier, P = 0.03878, one-sided McNemar's test. |
Classifier Construction
-
Leave-one-out cross-validation technique can be utilized for evaluating the performance of a classifier construction method of the subject invention. This approach tends towards high variance in accuracy estimates, but with low bias.
-
Within each step of the leave-one-out cross-validation (or fold), a classifier of the subject invention can be created on all available training data, then tested for accuracy by classifying the left-out example. In one embodiment, a classifier was constructed in two steps: first a gene selection procedure was performed with SAM and then a support vector machine was constructed.
-
In a related embodiment, the gene selection approach used was a univariate selection. SAM (significance analysis of microarrays) was the method chosen for selecting genes. Since gene selected was to be based on two classes (good vs. poor prognosis), the two-class SAM method can be used for selecting genes with the best d values. SAM calculates false discovery rates empirically through the use of permutation analysis. SAM provides an estimate of the false discovery rate (FDR) along with a list of genes considered significant relative to censored survival. This feature of SAM was used with this particular embodiment to select the number of genes that resulted in the smallest FDR possible. In one embodiment, this FDR was zero.
-
The set of 53 genes (significant genes, as described above) at a FDR of 28% was used in this particular embodiment. Using this subset of 53 genes, the samples were clustered as a way of visualizing the SAM results (see FIGS. 1A and 1B). Once the genes were selected using the SAM method, a linear support vector machine (SVM) was constructed. The software used for this approach can be implemented in a weka machine learning toolkit. A linear SVM was then chosen to reduce the potential for overfitting the data, given the small sample sizes and large dimensionality. One further advantage of this approach is the transparency of the constructed model, which is of particular interest when comparing the classifier of the subject invention on two different platforms (see below).
-
In another embodiment, using LOOCV via statistical analytic tools for comparing groups (i.e., parametric tests such as t-test/ANOVA; see also Dyrskjot L et al., “Identifying distinct classes of bladder carcinoma using microarrays,”
Nat. Genet., 33:90-6 (2003)), a list of 43 genes (from the 53 SAM selected genes as described above) was selected for use in constructing a second human colorectal cancer survival classifier, in accordance with the present invention. The list of 43 genes is provided in the following Table 3.
TABLE 3 |
|
|
Genes used in the cDNA classifier (selected by t-test) and ranked by selection |
frequency using LOOCV. |
Number | | | |
Times | GeneBank | UniGene |
Occurred | ID | ID | Description |
|
M*78 | AA045075 | Hs.62751 | syntaxin 7 |
M*78 | AA425320 | Hs.250461 | hypothetical protein; MDG1; similar to putative |
| | | microvascular endothelial differentiation gene 1; similar to |
| | | X98993 (PID: g1771560); |
| | | microvascular endothelial differentiation gene 1 product; |
| | | microvascularendothelial differentiation gene 1; |
| | | DKFZP564F1862 p |
M78 | AA437223 | Hs.46640 | adult retina protein |
M*78 | AA479270 | Hs.250802 | Diff33 protein homolog; KIAA1253 protein |
M*78 | AA486233 | Hs.2707 | G1 to S phase transition 1 |
M*78 | AA487274 | Hs.48950 | heptacellular carcinoma novel gene-3 protein; DAPPER1 |
M78 | AA488652 | Hs.4209 | HSPC235; ribosomal protein L2; Similar to ribosomal |
| | | protein, mitochondrial, L2 [Homo sapiens]; mitochondrial |
| | | ribosomal protein L37; ribosomal protein, mitochondrial, L2 |
| | | [Homo sapiens] |
M78 | AA694500 | Hs.116328 | hypothetical protein MGC33414; Similar to PR domain |
| | | containing 1, with ZNF domain |
M78 | AA704270 | Hs.189002 | Null |
M*78 | AA706226 | Hs.113264 | neuregulin 2 isoform 4 |
M*78 | AA709158 | Hs.42853 | put. DNA binding protein; put. DNA binding protein; cAMP |
| | | responsive element binding protein-like 1; Creb-related |
| | | protein |
M*78 | AA775616 | Hs.313 | OPN-b; osteopontin; secreted phosphoprotein 1 (osteopontin, |
| | | bone sialoprotein I, early T-lymphocyte activation 1) |
M78 | AA777892 | Hs.121939 | Null |
M*78 | AA873159 | Hs.182778 | apolipoprotein CI; apolipoprotein C-I variant II; |
| | | apolipoprotein C-I variant I |
M*78 | AA969508 | Hs.10225 | HEYL protein; hairy-related transcription factor 3; |
| | | hairy/enhancer-ofsplit related with YRPW motif-like |
M78 | AI203139 | Hs.180370 | hypothetical protein FLJ30934 |
M*78 | AI299969 | Hs.255798 | unnamed protein product; HN1 like; Unknown (protein for |
| | | MGC: 22947) |
M*78 | H17364 | Hs.80285 | CRE-BP1 family member; cyclic AMP response element |
| | | DNA-binding protein isoform 1 family; cAMP response |
| | | element binding protein (AA1-505); cyclic AMP response |
| | | element-binding protein (HB16); Similar to activating |
| | | transcription factor 2 [Homo sapiens]; act |
M78 | H17627 | Hs.83869 | unnamed protein |
M*78 | H19822 | Hs.2450 | KIAA0028; leucyl-tRNA synthetase, mitochondrial [Homo |
| | | sapiens]; leucyl-tRNA synthetase, mitochondrial [Homo |
| | | sapiens]; leucine-tRNA ligase precursor; leucine translase |
| | | [Homo sapiens] |
M*78 | H23551 | Hs.30974 | NADH dehydrogenase subunit 4 {Deirochelys reticularia} |
M78 | H62801 | Hs.125059 | Unknown (protein for IMAGE: 4309224) [Homo sapiens]; |
| | | hypothetical protein [Homo sapiens] |
M78 | H85015 | Hs.138614 | null |
M78 | N21630 | Hs.143039 | hypothetical protein PRO1942 |
M*78 | N36176 | Hs.108636 | membrane protein CH1; membrane protein CH1 [Homo |
| | | sapiens]; membrane protein CH1 [Homo sapiens]; membrane |
| | | protein CH1 [Homo sapiens] |
M*78 | N72847 | Hs.125221 | Alu subfamily SP sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
M78 | N92519 | Hs.1189 | Unknown (protein for MGC: 10231) [Homo sapiens] |
M*78 | R27767 | Hs.79946 | thyroid hormone receptor-associated protein, 150 kDa |
| | | subunit; Similar to thyroid hormone receptor-associated |
| | | protein, 150 kDa subunit [Homo sapiens];; |
M*78 | R34578 | Hs.111314 | null |
M78 | R38360 | Hs.145567 | unknown {Homo sapiens} |
M78 | R43597 | Hs.137149 | trehalase homolog T19F6.30 - Arabidopsis thaliana |
M78 | R43684 | Hs.165575 | dJ402G11.5 (novel protein similar to yeast and bacterial |
| | | predicted proteins) |
M*78 | W73732 | Hs.83634 | Null |
M*77 | AA450205 | Hs.8146 | translocation protein-1; Sec62; translocation protein 1; Dtrp1 |
| | | protein; membrane protein SEC62, S. cerevisiae, homolog of |
| | | [Homo sapiens]; |
M77 | AI081269 | Hs.184108 | Alu subfamily SX sequence contamination warning entry. |
M*77 | R59314 | Hs.170056 | null |
M*72 | AA702174 | Hs.75263 | pRb-interacting protein RbBP-36 |
M*70 | AI002566 | Hs.81234 | immunoglobin superfamily, member 3 |
M*63 | AA676797 | Hs.1973 | cyclin F |
M*62 | AA453508 | Hs.168075 | transportin; karyopherin (importin) beta 2; M9 region |
| | | interaction protein |
M62 | W93980 | Hs.59511 | null |
M*58 | AA045308 | Hs.7089 | insulin induced protein 2; INSIG-2 membrane protein |
M58 | AA953396 | Hs.127557 | null |
M52 | AA962236 | Hs.124005 | hypothetical protein MGC19780 |
M*50 | AA418726 | Hs.4764 | null |
M50 | R43713 | Hs.22945 | null |
M*41 | AA664240 | Hs.8454 | artifact-warning sequence (translated ALU class C) - human |
M*38 | AA477404 | Hs.125262 | hypothetical protein; unnamed protein product; GL003; |
| | | AAAS protein; adracalin; aladin |
M*37 | AA826237 | Hs.3426 | Era GTPase A protein; conserved ERA-like GTPase [Homo |
| | | sapiens]; ERA-W [Homo sapiens]; Era G-protein-like 1; |
| | | GTPase, human homolog of E. coli essential cell cycle |
| | | protein Era; era (E. coli Gprotein homolog)-like 1 [Homo |
| | | sapiens] |
M*30 | AA007421 | Hs.113992 | candidate tumor suppressor protein {Homo sapiens} |
M*30 | AA478952 | Hs.91753 | unnamed protein product; hypothetical protein [Homo |
| | | sapiens]; unnamed protein product [Homo sapiens]; |
| | | hypothetical protein [Homo sapiens] |
M62 | W93980 | Hs.59511 | Null |
M*58 | AA045308 | Hs.7089 | insulin induced protein 2; INSIG-2 membrane protein |
M58 | AA953396 | Hs.127557 | null |
52 | AA962236 | Hs.124005 | hypothetical protein MGC19780 |
*50 | AA418726 | Hs.4764 | null |
50 | R43713 | Hs.22945 | null |
*41 | AA664240 | Hs.8454 | artifact-warning sequence (translated ALU class C) - human |
*38 | AA477404 | Hs.125262 | hypothetical protein; unnamed protein product; GL003; |
| | | AAAS protein; adracalin; aladin |
*37 | AA826237 | Hs.3426 | Era GTPase A protein; conserved ERA-like GTPase [Homo |
| | | sapiens]; ERA-W [Homo sapiens]; Era G-protein-like 1; |
| | | GTPase, human homolog of E. coli essential cell cycle |
| | | protein Era; era (E. coli Gprotein homolog)-like 1 [Homo |
| | | sapiens] |
*30 | AA007421 | Hs.113992 | candidate tumor suppressor protein {Homo sapiens} |
*30 | AA478952 | Hs.91753 | unnamed protein product; hypothetical protein [Homo |
| | | sapiens]; unnamed protein product [Homo sapiens]; |
| | | hypothetical protein [Homo sapiens] |
30 | AA885096 | Hs.43948 | Alu subfamily SQ sequence contamination warning entry. |
28 | H29032 | Hs.7094 | null |
*24 | R10545 | Hs.148877 | dJ425C14.2 (Placental protein |
*22 | AA448641 | Hs.108371 | transcription factor; E2F transcription factor 4; p107/p130- |
| | | binding protein |
20 | R38266 | Hs.12431 | Unknown (protein for MGC: 30132) |
19 | H17543 | Hs.92580 | Alu subfamily J sequence contamination warning entry. |
11 | T81317 | Hs.189846 | Alu subfamily J sequence contamination warning entry. |
*9 | AA453790 | Hs.255585 | null |
9 | R22340 | null | unnamed protein product; chr2 synaptotagmin KIAA1228 |
| | | protein |
7 | AA987675 | Hs.176759 | null |
7 | N51543 | Hs.47292 | null |
*7 | N74527 | Hs.5420 | unnamed protein product |
*6 | AA121778 | Hs.95685 | null |
*6 | AA258031 | Hs.125104 | unnamed protein product; MUS81 endonuclease |
*6 | AA702422 | Hs.66521 | josephin MJD1; super cysteine rich protein; SCRP |
6 | T64924 | Hs.220619 | null |
*5 | R42984 | Hs.4863 | null |
*5 | R59360 | Hs.12533 | null |
*5 | R63816 | Hs.28445 | unnamed protein product |
5 | T49061 | Hs.8934 | HA-70 {Clostridium botulinum} |
4 | AA016210 | Hs.24920 | null |
4 | AA682585 | Hs.193822 | null |
4 | AA705040 | Hs.119646 | Alu subfamily J sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
4 | AA909959 | Hs.130719 | NESH; hypothetical protein; NESH protein [Homo sapiens]; |
| | | NESH protein; new molecule including SH3 [Homo sapiens] |
4 | AI240881 | Hs.89688 | complement receptor type 1-like protein {Homo sapiens} |
*3 | AA133215 | Hs.32989 | Receptor activity-modifying protein 1 precursor (CRLR |
| | | activity-modifying-protein 1) |
3 | AA699408 | Hs.168103 | prp28, U5 snRNP 100 kd protein; prp28, U5 snRNP 100 kd |
| | | protein [Homo sapiens] |
3 | AA910771 | Hs.130421 | null |
*3 | AI362799 | Hs.110757 | hypothetical protein; NNP3 [Homo sapiens] |
*3 | H51549 | Hs.21899 | UDP-galactose translocator; UDP-galactose transporter 1 |
| | | [Homo sapiens] |
3 | R06568 | Hs.187556 | null |
2 | AA001604 | Hs.204840 | null |
*2 | AA132065 | Hs.109144 | unknown; SMAP-5; Similar to hypothetical protein |
| | | AF140225 |
*2 | AA490493 | Hs.24340 | null |
2 | AA633845 | Hs.192156 | null |
*2 | AI261561 | Hs.182577 | Alu subfamily SQ sequence contamination warning entry. |
*2 | H81024 | Hs.180655 | Aik2; aurora-related kinase 2; serine/threonine kinase 12; |
| | | Unknown (protein for MGC: 11031) [Homo sapiens]; |
| | | Unknown (protein for MGC: 4243) [Homo sapiens] |
2 | N75004 | Hs.49265 | hypothetical protein {Plasmodium falciparum 3D7} |
2 | W96216 | Hs.110196 | NICE-1 protein |
1 | AA045793 | Hs.6790 | hypothetical protein; MDG1; similar to putative microvascular |
| | | endothelial differentiation gene 1; similar to X98993 |
| | | (PID: g1771560); microvascular endothelial differentiation gene 1 |
| | | product; microvascular endothelial differentiation gene 1; |
| | | DKFZP564F1862 p |
*1 | AA284172 | Hs.89385 | NPAT; predicted amino acids have three regions which share |
| | | similarity to annotated domains of transcriptional factor oct- |
| | | 1, nucleoluscytoplasm shuttle phosphoprotein and protein |
| | | kinases; NPAT; nuclear protein, ataxia-telangiectasia locus; |
| | | Similar to nuc |
*1 | AA411324 | Hs.67878 | interleukin-13 receptor; interleukin-13 receptor; interleukin |
| | | 13 receptor, alpha 1 [Homo sapiens]; Similar to interleukin 13 |
| | | receptor, alpha 1[Homo sapiens]; bB128O4.2.1 (interleukin |
| | | 13 receptor, alpha 1) [Homo |
| | | sapiens]; interleukin 13 receptor, alpha 1 |
*1 | AA448261 | Hs.139800 | high mobility group AT-hook 1 isoform b; nonhistone |
| | | chromosomal high-mobility group protein HMG-I/HMG-Y |
| | | [Homo sapiens] |
*1 | AA479952 | Hs.154145 | Alu subfamily SX sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
*1 | AA485752 | Hs.9573 | ATP-binding cassette, sub-family F, member 1; ATP-binding |
| | | cassette 50; ATP-binding cassette, sub-family F (GCN20), |
| | | member 1 [Homo sapiens];; |
*1 | AA504266 | Hs.8217 | nuclear protein SA-2; bA517O1.1 (similar to SA2 nuclear |
| | | protein); hypothetical protein [Homo sapiens]; stromal |
| | | antigen 2 [Homo sapiens] |
*1 | AA630376 | Hs.8121 | null |
*1 | AA634261 | Hs.25035 | null |
1 | AA701167 | Hs.191919 | Alu subfamily SB sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
*1 | AA703019 | Hs.114159 | small GTP-binding protein; RAB-8b protein; Unknown |
| | | (protein for MGC: 22321) [Homo sapiens] |
*1 | AA706041 | Hs.170253 | unnamed protein product [Homo sapiens]; hypothetical |
| | | protein FLJ23282 [Homo sapiens];; |
1 | AA773139 | Hs.66103 | null |
1 | AA776813 | Hs.191987 | hypothetical protein {Macaca fascicularis} |
*1 | AA862465 | Hs.71 | zinc-alpha2-glycoprotein precursor; Zn-alpha2-glycoprotein; |
| | | Znalpha2-glycoprotein; alpha-2-glycoprotein 1, zinc; alpha- |
| | | 2-glycoprotein 1, zinc [Homo sapiens];; |
*1 | AA977711 | Hs.128859 | null |
1 | AI288845 | Hs.105938 | putative chemokine receptor; putative chemokine receptor; |
| | | chemokine receptor X; C—C chemokine receptor 6. (CCR6) |
| | | (Evidence is not experimental); chemokine (C—C motif) |
| | | receptor-like 2 [Homo sapiens] |
*1 | H15267 | Hs.210863 | null |
1 | H18956 | Hs.21035 | unnamed protein product [Homo sapiens] |
1 | H73608 | Hs.94903 | null |
*1 | H99544 | Hs.153445 | unknown; endothelial and smooth muscle cell-derived |
| | | neuropilin-like protein [Homo sapiens]; endothelial and |
| | | smooth muscle cell-derived neuropilin-like protein; |
| | | coagulation factor V/VIII-homology domains protein 1 |
| | | [Homo sapiens] |
*1 | N45282 | Hs.201591 | calcitonin receptor-like |
*1 | N48270 | Hs.45114 | Similar to golgi autoantigen, golgin subfamily a, member 6 |
| | | [Homo sapiens] |
1 | N59451 | Hs.48389 | null |
*1 | N95226 | Hs.22039 | KIAA0758 protein; |
1 | R37028 | Hs.20956 | cytochrome bd-type quinol oxidase subunit I related protein |
| | | {Thermoplasma acidophilum} |
1 | R66605 | Hs.182485 | Unknown (protein for IMAGE: 4843317) {Homo sapiens} |
*1 | T51004 | Hs.167847 | null |
1 | T51316 | null | null |
1 | T72535 | Hs.189825 | null |
*1 | W72103 | Hs.236443 | beta-spectrin 2 isoform 2 |
|
Mdenotes genes that were used to classify 75% of all tumors, and genes appearing in both the cDNA classifier and the U133A-limited cDNA classifier are marked by *. |
Any and all of the nucleotide and/or amino acid sequences associated with the accession numbers listed in Table 3 are hereby incorporated by reference.
-
In yet another embodiment, a third human colorectal cancer survival classifier, in accordance with the present invention, was prepared using U133A-limited genes selected by LOOCV via statistical analytic tools (i.e., t-test). The list of U133A-limited genes selected using LOOCV via t-test is provided in the following Table 4. The named genes common to both the original classifier (a set of 43 genes) and the U133A-limited classifier are marked with an asterisk. Table 5 illustrates seven genes selected by SAM survival analysis, where osteopontin and neuregulin are noted to be present and in common with the gene lists for all classifiers. In Table 5, genes denoted with (+) indicate a positive correlation to survival time and genes without the (+) notation indicate a negative correlation in survival time (over expression in poor prognosis cases)
TABLE 4 |
|
|
Genes used in U133A-limited cDNA classifier (selected by t-test) and ranked |
by selection frequency using LOOCV. |
Number | | | |
Times | GeneBank | UniGene |
Occurred | ID | ID | Description |
|
M*78 | AA007421 | Hs.113992 | candidate tumor suppressor protein |
M*78 | AA045075 | Hs.62751 | syntaxin 7 |
M*78 | AA045308 | Hs.7089 | insulin induced protein 2, INSIG-2 membrane protein |
M*78 | AA418726 | Hs.4764 | null |
M*78 | AA425320 | Hs.250461 | hypothetical protein; MDG1; similar to putative |
| | | microvascular endothelial differentiation gene 1; similar to |
| | | X98993 (PID: g1771560); microvascular endothelial |
| | | differentiation gene 1 product; microvascular endothelial |
| | | differentiation gene 1; DKFZP564F1862 p |
M*78 | AA450205 | Hs.8146 | translocation protein-1; Sec62; translocation protein 1; Dtrp1 |
| | | protein; membrane protein SEC62, S. cerevisiae, homolog of |
| | | [Homo sapiens]; |
M*78 | AA453508 | Hs.168075 | transportin; karyopherin (importin) beta 2; M9 region |
| | | interaction protein |
M*78 | AA453790 | Hs.255585 | null |
M*78 | AA477404 | Hs.125262 | hypothetical protein; unnamed protein product; GL003; |
| | | AAAS protein; adracalin; aladin; adracalin |
M*78 | AA478952 | Hs.91753 | unnamed protein product |
M*78 | AA479270 | Hs.250802 | Diff33 protein homolog; KIAA1253 protein |
M*78 | AA486233 | Hs.2707 | G1 to S phase transition 1 [Homo sapiens] |
M*78 | AA487274 | Hs.48950 | heptacellular carcinoma novel gene-3 protein; DAPPER1 |
| | | [Homo sapiens]; unnamed protein product [Homo sapiens] |
M*78 | AA664240 | Hs.8454 | artifact-warning sequence (translated ALU class C) - human |
M*78 | AA676797 | Hs.1973 | cyclin F |
M*78 | AA702174 | Hs.75263 | pRb-interacting protein RbBP-36 |
M*78 | AA706226 | Hs.113264 | neuregulin 2 isoform 4 |
M*78 | AA709158 | Hs.42853 | put. DNA binding protein; put. DNA binding protein; cAMP |
| | | responsive element binding protein-like 1; Creb-related |
| | | protein [Homo sapiens] |
M*78 | AA775616 | Hs.313 | OPN-b; osteopontin; secreted phosphoprotein 1 (osteopontin, |
| | | bone sialoprotein I, early T-lymphocyte activation 1); |
| | | secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, |
| | | early T-lymphocyte activation 1) [Homo sapiens]; secreted |
| | | phosphoprotein 1 (ost |
M*78 | AA826237 | Hs.3426 | Era GTPase A protein; conserved ERA-like GTPase [Homo |
| | | sapiens]; ERA-W [Homo sapiens]; Era G-protein-like 1; |
| | | GTPase, human homolog of E. coli essential cell cycle |
| | | protein Era; era (E. coli G-protein homolog)-like 1 [Homo |
| | | sapiens] |
M*78 | AA873159 | Hs.182778 | apolipoprotein CI; apolipoprotein CI; apolipoprotein C-I; |
| | | apolipoprotein C-I precursor; apolipoprotein C-I variant II; |
| | | apolipoprotein C-I variant I; Similar to apolipoprotein C-I |
| | | [Homo sapiens] |
M*78 | AA969508 | Hs.10225 | HEYL protein; hairy-related transcription factor 3; |
| | | hairy/enhancer-of-split related with YRPW motif-like [Homo |
| | | sapiens] |
M*78 | AI002566 | Hs.81234 | immunoglobin superfamily, member 3 |
M*78 | AI299969 | Hs.255798 | unnamed protein product [Homo sapiens]; HN1 like [Homo |
| | | sapiens]; Unknown (protein for MGC: 22947) [Homo |
| | | sapiens]; HN1 like [Homo sapiens] |
M*78 | H17364 | Hs.80285 | CRE-BP1 family member; cyclic AMP response element |
| | | DNA-binding protein isoform 1 family; cAMP response |
| | | element binding protein (AA 1-505); cyclic AMP response |
| | | element-binding protein (HB16); Similar to activating |
| | | transcription factor 2 [Homo sapiens]; act |
M*78 | H19822 | Hs.2450 | KIAA0028; leucyl-tRNA synthetase, mitochondrial [Homo |
| | | sapiens]; leucyl-tRNA synthetase, mitochondrial [Homo |
| | | sapiens]; leucine-tRNA ligase precursor; leucine translase |
| | | [Homo sapiens] |
M*78 | H23551 | Hs.30974 | NADH dehydrogenase subunit 4 {Deirochelys reticularia} |
M*78 | N36176 | Hs.108636 | membrane protein CH1; membrane protein CH1 [Homo |
| | | sapiens]; membrane protein CH1 [Homo sapiens]; membrane |
| | | protein CH1 [Homo sapiens] |
M*78 | N72847 | Hs.125221 | Alu subfamily SP sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
M*78 | R10545 | Hs.148877 | dJ425C14.2 (Placental protein |
M*78 | R27767 | Hs.79946 | thyroid hormone receptor-associated protein, 150 kDa |
| | | subunit; Similar to thyroid hormone receptor-associated |
| | | protein, 150 kDa subunit [Homo sapiens];; |
M*78 | R34578 | Hs.111314 | null |
M*78 | R59314 | Hs.170056 | null |
M*78 | W73732 | Hs.83634 | null |
M*74 | AA448641 | Hs.108371 | transcription factor; E2F transcription factor 4; p107/p130- |
| | | binding protein [Homo sapiens]; E2F transcription factor 4, |
| | | p107/p130-binding [Homo sapiens]; E2F transcription factor |
| | | 4, p107/p130-binding [Homo sapiens]; |
M*68 | R59360 | Hs.12533 | null |
M*63 | AA121778 | Hs.95685 | null |
M*59 | H51549 | Hs.21899 | UDP-galactose translocator; UDP-galactose transporter 1 |
| | | [Homo sapiens] |
*57 | H81024 | Hs.180655 | Aik2; aurora-related kinase 2; serine/threonine kinase 12; |
| | | serine/threonine kinase 12 [Homo sapiens]; Unknown |
| | | (protein for MGC: 11031) [Homo sapiens]; Unknown (protein |
| | | for MGC: 4243) [Homo sapiens] |
*56 | AA490493 | Hs.24340 | 0 |
*56 | R42984 | Hs.4863 | null |
*53 | AA258031 | Hs.125104 | unnamed protein product [Homo sapiens]; MUS81 |
| | | endonuclease [Homo sapiens]; MUS81 endonuclease [Homo |
| | | sapiens] |
*52 | AA133215 | Hs.32989 | Receptor activity-modifying protein 1 precursor (CRLR |
| | | activity-modifying-protein 1) |
*52 | R63816 | Hs.28445 | unnamed protein product [Homo sapiens] |
*51 | N95226 | Hs.22039 | KIAA0758 protein |
*45 | N74527 | Hs.5420 | unnamed protein product {Homo sapiens} |
*36 | AA702422 | Hs.66521 | josephin MJD1; super cysteine rich protein; SCRP |
*29 | AI261561 | Hs.182577 | Alu subfamily SQ sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
*28 | AA132065 | Hs.109144 | unknown; SMAP-5; Similar to hypothetical protein |
| | | AF140225 [Homo sapiens]; Similar to hypothetical protein |
| | | AF140225 [Homo sapiens]; unnamed protein product [Homo |
| | | sapiens]; unknown [Homo sapiens]; hypothetical protein |
| | | AF140225 [Homo sapiens] |
*28 | AI362799 | Hs.110757 | hypothetical protein; NNP3 [Homo sapiens] |
*27 | AA045793 | Hs.6790 | hypothetical protein; MDG1; similar to putative |
| | | microvascular endothelial differentiation gene 1; similar to |
| | | X98993 (PID: g1771560); microvascular endothelial |
| | | differentiation gene 1 product; microvascular endothelial |
| | | differentiation gene 1; DKFZP564F1862 p |
*27 | AA284172 | Hs.89385 | NPAT; predicted amino acids have three regions which share |
| | | similarity to annotated domains of transcriptional factor oct- |
| | | 1, nucleolus-cytoplasm shuttle phosphoprotein and protein |
| | | kinases; NPAT; nuclear protein, ataxia-telangiectasia locus; |
| | | Similar to nuc |
24 | N51632 | Hs.75353 | The KIAA0123 gene product is related to rat general |
| | | mitochondrial matrix processing protease (MPP).; Unknown |
| | | (protein for IMAGE: 3632957) [Homo sapiens]; Unknown |
| | | (protein for IMAGE: 3857242) [Homo sapiens]; inositol |
| | | polyphosphate-5-phosphatase, 72 kDa; KIAA0 |
23 | AA482110 | Hs.4900 | Unknown gene product; PRO0915; CUA001; hypothetical |
| | | protein [Homo sapiens]; hypothetical protein [Homo sapiens] |
22 | AA485450 | Hs.132821 | flavin containing monooxygenase 2; flavin containing |
| | | monooxygenase 2 [Homo sapiens] |
*19 | AA699408 | Hs.168103 | prp28, U5 snRNP 100 kd protein; prp28, U5 snRNP 100 kd |
| | | protein [Homo sapiens] |
18 | N70777 | Hs.49927 | BA103J18.1.2 (novel protein, isoform 2) [Homo sapiens] |
16 | AA993736 | Hs.169838 | hypothetical protein; vesicle-associated membrane protein 4 |
| | | [Homo sapiens]; Similar to vesicle-associated membrane |
| | | protein 4 [Homo sapiens] |
15 | AI139498 | Hs.151899 | delta sarcoglycan; delta-sarcoglycan isoform 2; Sarcoglyan, |
| | | delta (35 kD dystrophin-associated glycoprotein); dystrophin |
| | | associated glycoprotein, delta sarcoglycan; 35 kD dystrophin- |
| | | associated glycoprotein [Homo sapiens] |
15 | N59721 | Hs.21858 | glia-derived nexin precursor; serine (or cysteine) proteinase |
| | | inhibitor, clade E (nexin, plasminogen activator inhibitor type |
| | | 1), member 2; protease inhibitor 7 (protease nexin I); glia- |
| | | derived nexin [Homo sapiens]; similar to serine (or cysteine) |
| | | protein |
14 | AA431885 | Hs.5591 | MAP kinase-interacting serine/threonine kinase 1; MAP |
| | | kinase |
| | | interacting kinase 1 [Homo sapiens] |
14 | AA911661 | Hs.2733 | Hox2H protein (AA 1-356); K8 homeo protein; HOX2.8 gene |
| | | product; HOXB2 protein; HOX-2.8 protein (77 AA); homeo |
| | | box B2; homeo box 2H; homeobox protein Hox-B2; K8 |
| | | home protein [Homo sapiens]; |
13 | AA775865 | Hs.7579 | KIAA1192 protein; HSPC273; unnamed protein product; |
| | | hypothetical protein FLJ10402 [Homo sapiens]; unnamed |
| | | protein product [Homo sapiens]; hypothetical protein |
| | | FLJ10402 [Homo sapiens]; hypothetical protein [Homo |
| | | sapiens]; unnamed protein product [Homo sapiens] |
13 | R30941 | Hs.24064 | signal transducer and activator of transcription Stat5B; |
| | | transcription factorStat5b; STAT5B_CDS [Homo sapiens]; |
| | | signal transducer and activator of transcription 5B; signal |
| | | transducer and activator of transcription 5; transcription |
| | | factor STAT5B [Homo sapiens] |
*11 | AA703019 | Hs.114159 | small GTP-binding protein; RAB-8b protein; Unknown |
| | | (protein for MGC: 22321) [Homo sapiens] |
11 | AA777192 | Hs.47062 | RNA Polymerase II subunit 14.5 kD; DNA directed RNA |
| | | polymerase II polypeptide I; DNA directed RNA polymerase |
| | | II 14.5 kda polypeptide [Homo sapiens]; polymerase (RNA) |
| | | II (DNA directed) polypeptide I (14.5 kD) [Homo sapiens] |
*10 | W72103 | Hs.236443 | beta-spectrin 2 isoform 2 [Homo sapiens] |
*9 | H15267 | Hs.210863 | null |
8 | H17638 | Hs.17930 | dJ1033B10.2.2 (chromosome 6 open reading frame 11 |
| | | BING4), isoform 2) [Homo sapiens] |
8 | R60193 | Hs.11637 | null |
7 | R92717 | Hs.170129 | choroideremia-like Rab escort protein 2; dJ317G22.3 |
| | | (choroideremia-like (Rab escort protein 2)) |
*6 | AA706041 | Hs.170253 | unnamed protein product [Homo sapiens]; hypothetical |
| | | protein FLJ23282 [Homo sapiens];; |
*5 | AA411324 | Hs.67878 | interleukin-13 receptor; interleukin-13 receptor; interleukin |
| | | 13 receptor, alpha 1 [Homo sapiens]; Similar to interleukin |
| | | 13 receptor, alpha 1 [Homo sapiens]; bB128O4.2.1 |
| | | (interleukin 13 receptor, alpha 1) [Homo sapiens]; interleukin |
| | | 13 receptor, alpha 1 |
*5 | AA504266 | Hs.8217 | nuclear protein SA-2; bA517O1.1 (similar to SA2 nuclear |
| | | protein); hypothetical protein [Homo sapiens]; stromal |
| | | antigen 2 [Homo sapiens] |
5 | AA932696 | Hs.8022 | TU3A protein; TU3A protein [Homo sapiens] |
5 | AA973494 | Hs.153003 | serine/threonine kinase; myristilated and palmitylated serine- |
| | | threonine kinase MPSK; protein kinase expressed in day 12 |
| | | fetal liver; F5-2; serine/threonine kinase KRCT; |
| | | erine/threonine kinase 16 [Homo sapiens]; |
5 | N45100 | Hs.34871 | HRIHFB2411; KIAA0569 gene product; Smad interacting |
| | | protein 1 [Homo sapiens]; smad-interacting protein-1 [Homo |
| | | sapiens] |
4 | AA418410 | Hs.9880 | cyclophilin; U-snRNP-associated cyclophilin; peptidyl prolyl |
| | | isomerase H (cyclophilin H) [Homo sapiens] |
4 | AA725641 | Hs.154397 | WD-repeat protein |
4 | AA954482 | Hs.222677 | SSX1; synovial sarcoma, X breakpoint 1 [Homo sapiens]; |
| | | synovial sarcoma, X breakpoint 8 [Homo sapiens]; synovial |
| | | sarcoma, X breakpoint 1; sarcoma, synovial, X-chromosome- |
| | | related 1; SSX1 protein [Homo sapiens] |
4 | H45391 | Hs.31793 | null |
4 | T86932 | Hs.131924 | T-cell death-associated gene 8; similar to G protein-coupled |
| | | receptor [Homo sapiens] |
3 | AA279188 | Hs.86947 | disintegrin and metalloprotease domain 8 precursor |
*3 | AA485752 | Hs.9573 | ATP-binding cassette, sub-family F, member 1; ATP-binding |
| | | cassette 50; ATP-binding cassette, sub-family F (GCN20), |
| | | member 1 [Homo sapiens];; |
3 | AA680132 | Hs.55235 | sphingomyelin phosphodiesterase 2, neutral membrane |
| | | (neutral |
| | | sphingomyelinase); Unknown (protein for MGC: 1617) |
| | | [Homo sapiens] |
*3 | AA977711 | Hs.128859 | null |
3 | W93370 | Hs.174219 | NKG2E; type II integral membrane protein; killer cell lectin- |
| | | like receptor subfamily C, member 3; killer cell lectin-like |
| | | receptor subfamily C, member 3 isoform NKG2-H; NKG2E |
| | | [Homo sapiens]; NKG2E [Homo |
| | | sapiens]; NKG2E [Homo sapiens] |
2 | AA036727 | Hs.180236 | null |
2 | AA071075 | Hs.25523 | Alu subfamily SP sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
2 | AA464612 | Hs.190161 | PTD017; HSPC183; PTD017 protein [Homo sapiens]; |
| | | mitochondrial ribosomal protein S18B; mitochondrial |
| | | ribosomal protein S18-2; mitochondrial 28S ribosomal |
| | | protein S18-2 [Homo sapiens] |
2 | AA481250 | Hs.154138 | chitinase precursor; chitinase 3-like 2; chondrocyte protein |
| | | 39; chitinase 3-like 2 [Homo sapiens] |
2 | AA598659 | Hs.168516 | NuMA protein {Homo sapiens} |
2 | AA682905 | Hs.8004 | huntingtin-associated protein interacting protein |
2 | R17811 | Hs.77897 | splicing factor SF3a60; pre-mRNA splicing factor SF3a |
| | | (60 kD), similar to S. cerevisiae PRP9 (spliceosome- |
| | | associated protein 61); splicing factor 3a, subunit 3, 60 kD |
| | | [Homo sapiens]; Similar to splicing factor 3a, subunit 3, |
| | | 60 kD [Homo sapiens] |
2 | W93592 | Hs.47343 | hWNT5A; wingless-type MMTV integration site family, |
| | | member 5A precursor; proto-oncogene Wnt-5A precursor; |
| | | WNT-5A protein precursor [Homo sapiens] |
1 | AA017301 | Hs.60796 | artifact-warning sequence (translated ALU class C) - human |
1 | AA046406 | Hs.100134 | unnamed protein product [Homo sapiens]; hypothetical |
| | | protein FLJ12787 [Homo sapiens] |
1 | AA256304 | Hs.172648 | Unknown (protein for MGC: 9448) [Homo sapiens]; distal- |
| | | less homeo box 7 [Homo sapiens]; distal-less homeobox 4, |
| | | isoform a; beta protein 1 [Homo sapiens] |
1 | AA416759 | Hs.239760 | Unknown (protein for MGC: 2503) [Homo sapiens]; unnamed |
| | | protein product [Homo sapiens] |
*1 | AA448261 | Hs.139800 | high mobility group AT-hook 1 isoform b; nonhistone |
| | | chromosomal highmobility group protein HMG-I/HMG-Y |
| | | [Homo sapiens] |
1 | AA452130 | Hs.28219 | Alu subfamily SX sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
1 | AA457528 | Hs.22979 | unnamed protein product [Homo sapiens]; hypothetical |
| | | protein FLJ13993 [Homo sapiens]; FLJ00167 protein [Homo |
| | | sapiens] |
1 | AA460542 | Hs.121849 | microtubule-associated proteins 1A/1B light chain 3; |
| | | microtubuleassociated proteins 1A/1B light chain 3; |
| | | microtubule-associated proteins 1A/1B light chain 3 [Homo |
| | | sapiens]; microtubule-associated proteins 1A/1B light chain 3 |
| | | [Homo sapiens] |
*1 | AA479952 | Hs.154145 | Alu subfamily SX sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
1 | AA481507 | Hs.159492 | unnamed protein product [Homo sapiens] |
1 | AA504342 | Hs.7763 | null |
1 | AA598970 | Hs.7918 | unnamed protein product; hypothetical protein; dJ453C12.6.2 |
| | | (uncharacterized hypothalamus protein (isoform 2)); |
| | | hypothetical protein [Homo sapiens]; uncharacterized |
| | | hypothalamus protein HSMNP1 [Homo sapiens] |
*1 | AA630376 | Hs.8121 | null |
*1 | AA634261 | Hs.25035 | null |
1 | AA677254 | Hs.52002 | CT-2; CD5 antigen-like (scavenger receptor cysteine rich |
| | | family); bA120D12.1 (CD5 antigen-like (scavenger receptor |
| | | cysteine rich family)) [Homo sapiens]; CD5 antigen-like |
| | | (scavenger receptor cysteine rich family) [Homo sapiens] |
1 | AA757564 | Hs.13214 | Probable G protein-coupled receptor GPR27 (Super |
| | | conserved receptor expressed in brain 1). [Human] |
1 | AA775888 | Hs.163151 | null |
1 | AA844864 | Hs.4158 | regenerating protein I beta; regenerating islet-derived 1 beta |
| | | precursor; lithostathine 1 beta; regenerating protein I beta; |
| | | secretory pancreatic stone protein 2 [Homo sapiens] |
*1 | AA862465 | Hs.71 | zinc-alpha2-glycoprotein precursor; Zn-alpha2-glycoprotein; |
| | | Zn-alpha2-glycoprotein; alpha-2-glycoprotein 1, zinc; alpha- |
| | | 2-glycoprotein 1, zinc [Homo sapiens];; |
1 | AA989139 | Hs.16608 | candidate tumor suppressor protein; candidate tumor |
| | | suppressor protein [Homo sapiens] |
1 | AI253017 | Hs.183438 | U4/U6 snRNP-associated 61 kDa protein {Homo sapiens} |
1 | AI394426 | Hs.57732 | acid phosphatase {Homo sapiens} |
*1 | H99544 | Hs.153445 | unknown; endothelial and smooth muscle cell-derived |
| | | neuropilin-like protein [Homo sapiens]; endothelial and |
| | | smooth muscle cell-derived neuropilin-like protein; |
| | | coagulation factor V/VIII-homology domains protein 1 |
| | | [Homo sapiens] |
1 | N41021 | Hs.114408 | Toll/interleukin-1 receptor-like protein 3; Toll-like receptor |
| | | 5; Toll-like receptor 5 [Homo sapiens]; toll-like receptor 5; |
| | | Toll/interleukin-1 receptor-like protein 3 [Homo sapiens] |
*1 | N45282 | Hs.201591 | calcitonin receptor-like |
1 | N46845 | Hs.144287 | hairy/enhancer-of-split related with YRPW motif 2; basic |
| | | helix-loop-helix factor 1; HES-related repressor protein 1 |
| | | HERP1; GRIDLOCK; basichelix-loop-helix protein; hairy- |
| | | related transcription factor 2; hairy/enhancer-of-split related |
| | | with YRPW motif 2 [H |
*1 | N48270 | Hs.45114 | Similar to golgi autoantigen, golgin subfamily a, member 6 |
| | | [Homo sapiens] |
1 | N59846 | Hs.177812 | Unknown (protein for MGC: 41314) {Mus musculus} |
1 | R16760 | Hs.20509 | HBV pX associated protein-8 |
1 | R44546 | Hs.82563 | dJ526I14.2 (KIAA0153 (similar |
1 | R92994 | Hs.1695 | metalloelastase; metalloelastase; matrix metalloproteinase 12 |
| | | (macrophage elastase) |
*1 | T51004 | Hs.167847 | null |
1 | T56281 | Hs.8765 | metallothionein I-F; RNA helicase-related protein [Homo |
| | | sapiens]; |
| | | metallothionein 1F [Homo sapiens] |
1 | T70321 | Hs.247129 | G3a protein; Apo M; apolipoprotein M; Unknown (protein |
| | | for |
| | | MGC: 22400) [Homo sapiens]; apolipoprotein M; NG20-like |
| | | protein [Homo sapiens] |
1 | W45025 | Hs.170268 | Alu subfamily SX sequence contamination warning entry. |
| | | [Human] {Homo sapiens} |
|
Mdenotes genes used to classify 75% of all tumors, and genes appearing in both the cDNA classifier and U133A-limited cDNA classifier are marked by *. |
-
Any and all of the nucleotide and/or amino acid sequences associated with the accession numbers listed in Table 4 are hereby incorporated by reference.
TABLE 5 |
|
|
Censored survival analysis using SAM; seven genes selected with |
median estimated FDR of 13.5%. |
GeneBank | UniGene | |
ID | ID | Description |
|
N36176 | Hs.108636 | membrane protein CH1 |
AA149253 | Hs.107987 | N/A |
AA425320 | Hs.250461 | hypothetical protein; MDG1; similar to putative |
| | microvascular endothelial differentiation |
| | gene 1; similar to X98993 (PID: g1771560) |
AA775616 | Hs.313 | OPN-b; osteopontin; secreted phosphoprotein 1 |
| | (osteopontin, bone sialoprotein I, early |
| | T-lymphocyte activation 1) |
N72847 | Hs.125221 | N/A |
AA706226 | Hs.113264 | neuregulin 2 isoform 4 |
+AA883496 | Hs.125778 | N/A |
|
Any and all of the nucleotide and/or amino acid sequences associated with the accession numbers listed in Table 5 are hereby incorporated by reference. |
Cross Platform Validation
-
Systems and methods of the subject invention can be tested by applying a classifier to an immediately available, well-annotated, independent test set of colon cancer tumor samples (Denmark, as described above) run on the Affymetrix platform. Using database software such as the Resourcer software from TIGR (see also Tsai J et al., “RESOURCER: a database for annotating and linking microarray resources within and across species,” Genome Biol, 2:software0002.1-0002.4 (2001)), genes can be mapped out from the cDNA chip to a corresponding gene on the Affymetrix platform.
-
The linkage is done by common Unigene IDs.
-
In one embodiment, 12,951 genes (out of 32,000) were mapped to an Affymetrix U133A GeneChip. In certain instances, probes on the cDNA chip are unknown expressed sequence tag markers (ESTs) which can reduce the number of usable genes identified. Thus, a classifier of the subject invention can address this lack of correspondence in platforms. Accordingly, in a related embodiment, a U133A-limited cDNA classifier was constructed in accordance with the subject invention by using the identical approach on this reduced set of overlapping genes.
-
With the U133A-limited cDNA classifier, only those cDNA probes are chosen that (according to Resourcerer) mapped to an Affymetrix probe set. This approach enables cross-platform comparison. For example, the training set samples were used together with the test set tumor samples in a flip-dye design. The end expression value from a cDNA probe is then the log2 of the training set to test set sample ratio. This same reference RNA was used on two U133A Affymetrix chips.
-
Once the U133A-limited cDNA classifier was constructed, a linear scaling factor based on the expression of a common training set (H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla.) sample applied to both the cDNA microarrays and the U133A GeneChips, was applied equally to all Affymetrix samples (training set as well as test set samples from DENMARK). Using this assumption, the U133A chip value corresponding to a cDNA probe is the ratio of training set to test set sample (on U133A chips). Each of the Affymetrix U133A arrays (both the test set and the reference samples) was scaled to a constant average intensity (150) prior to taking the ratio and the test sample chip values were averaged.
-
The results of a full LOOCV for the U133A-limited classifier on the test set sample (Moffitt Cancer Center cDNA microarray data set; original 78 samples) are shown in Tables 6A-6C. The accuracy of the U133A-limited classifier was 72% (80% sensitivity/59% specificity), which contrasted from the original cDNA classifier results (90%, P=0.001154). Many ESTs were selected both in the SAM survival analysis and in the original cDNA-based classifier, indicating unknown genes (ESTs) may be very important to colorectal cancer outcome. The U133A-limited classifier was not significantly different, however, than the Dukes' staging (77%), P=0.4862 using a two-sided McNemar's test, and still significantly discriminated the two groups, as can be seen in FIG. 3B (P<0.001).
-
FIGS. 3A through 3C illustrate survival curves for molecular classifiers in accordance with the subject invention. Specifically,
FIG. 3A illustrates the survival curve for a cDNA classifier of the subject invention on the 78 training set samples (LOOCV);
FIG. 3B illustrates the survival curve for the U133A-limited cDNA classifier (LOOCV); and
FIG. 3C illustrates the survival curve for an independent test set classification (Denmark test set sample). A large difference in sensitivity can be seen between the Dukes' method and the classifier (Tables 6A-6C). The confusion matrix and accuracy rates by Dukes' stage are also presented in Tables 6A-6C.
TABLE 6A |
|
|
LOOCV Accuracy of Dukes' vs. Molecular Staging for all tumors. |
| Classification | Total | | |
| Method | Accuracy | Sensitivity | Specificity |
| |
| Dukes' | 76.9% | 63% | 97% |
| Staging |
| Molecular | 71.8% | 80% | 59% |
| Staging |
| |
-
TABLE 6B |
|
|
Comparison of Molecular Staging and Dukes' Staging Accuracy |
Dukes' |
Molecular |
Dukes' |
Stage |
Staging |
Staging |
|
Adenoma |
67% |
100% |
B |
70% |
70% |
C |
64% |
55% |
D |
|
80% |
97% |
|
-
TABLE 6C |
|
|
Confusion Matrix of cDNA Classifier Results |
|
Observed/Predicted |
Poor |
Good |
Totals |
|
|
|
Poor |
38 |
8 |
46 |
|
Good |
14 |
18 |
32 |
|
Total |
52 |
26 |
78 |
|
|
-
With respect to comparing the predictive power of a classifier of the subject invention to Dukes' staging, the U133A-limited classifier was tested on the test set of colorectal cancer samples from Denmark that were profiled on the Affymetrix U133A platform. The normalized and scaled test-set data were evaluated with the U133A-limited cDNA classifier. Because the Denmark cases included only Dukes' stages B and C, classification of outcome by Dukes' staging would predict all samples to be of good prognosis. The accuracy of the cDNA classifier was reduced from 72% in LOOCV of the training set (Tables 6A-6C) to 68% in the Denmark cross-platform test set (Tables 7A-7C). A diminished accuracy (4%) was expected due to the limitations imposed by cross-platform analyses, however this reduction was very small compared to that caused by limiting the classifier gene set to U133A content. This result is not significantly different from that achieved by classification using Dukes' staging (64%, P=0.7194 using a two sided McNemar's test) and is better than other reported results (47%) (see Sorlie T et al., “Repeated observation of breast tumor subtypes in independent gene expression data sets,”
Proc Natl Acad Sci USA, 100:8418-23 (2003)) for cross-platform analyses where scaling was required. Moreover, the classifier of the subject invention was able to predict the outcome for poor prognosis patients (sensitivity) with an accuracy of 55% whereas 0% would be predicted correctly by Dukes' staging.
TABLE 7A |
|
|
Accuracy of U133A limited Molecular Staging on Cross-Platform |
Denmark Independent Test Set. |
Classification Method | Total Accuracy | Sensitivity | Specificity |
|
Dukes' Staging | 64% | 0% | 100% |
Molecular Staging | 68.5% | 55% | 75% |
|
-
TABLE 7B |
|
|
Comparison of Dukes' Staging and U133A limited Molecular Staging |
Accuracy on Cross-Platform Denmark Independent Test Set. |
|
Dukes' Stage |
Molecular Staging |
Dukes' Staging |
|
|
|
B |
64% |
79% |
|
C |
70% |
58% |
|
|
-
TABLE 7C |
|
|
Confusion Matrix of U133A limited Molecular Staging Results on |
Cross-Platform Denmark Independent Test Set |
|
Observed/Predicted |
Poor |
Good |
Totals |
|
|
|
Poor |
17 |
14 |
31 |
|
Good |
14 |
43 |
57 |
|
Total |
31 |
57 |
88 |
|
|
-
The present invention provides a colon cancer clinical classifier with significant accuracy in LOOCV that exceeds that of Dukes staging. The utility of the classifier of the subject invention can be validated, such as against in an independent colon cancer population using a completely different microarray platform. The gene classifier of the subject invention can be based on a core set of genes that have biological significance for any type of cancer, including human colon cancer progression.
-
Application of Prognosis Classifier with Therapy
-
The benefit of adjuvant chemotherapy for colorectal cancer appears limited to patients with Dukes stage C disease where the cancer has metastasized to lymph nodes at the time of diagnosis. For this reason, the clinicopathological Dukes' staging system is critical for determining how adjuvant therapy is administered. Unfortunately, as noted above, Dukes' staging is not very accurate in predicting overall survival and thus its application likely results in the treatment of a large number of patients to benefit an unknown few. Alternatively, there are a number of patients who would benefit from therapy that do not receive it based on the Dukes' staging system. Accordingly, an important contribution of the prognosis/survival classifier of the present invention is the ability to identify those Dukes' stage B and C cases for which chemotherapy may be beneficial.
-
The molecular staging/classifier of the subject invention provides more accurate predictions of patient outcome than is currently possible with current clinical staging systems, which may, in fact, misclassify patients. In accordance with the present invention, a set of genes is derived from a genome wide analysis of gene expression using known microarray analysis techniques (i.e., SAM). By clustering groups of patients with good and bad prognoses, it is illustrated that the prognosis/classifier of the subject invention presents outcome-rich information. In a further aspect of the present invention, a supervised learning analysis can be used to identify a core set of informative genes. In a preferred embodiment, a core set of 43 genes was identified that appeared in 75% of the cross validation iterations and accurately predicted colorectal cancer survival. This core set was derived from a 32,000-element cDNA microarray that included both named and unnamed genes. This gene set was highly accurate in predicting survival when compared with Dukes' staging data from the same patients.
-
A means for validating a prognosis/survival classifier is provided by the present invention. In one embodiment, to validate a cDNA-based classifier for human colorectal cancer, a normalized and scaled oligonucleotide-based colorectal cancer database from Denmark was evaluated based on the Affymetrix U133A GeneChip™. In a related embodiment, a colorectal cancer classifier (U133A-based cDNA classifier) was produced on the training data set using a limited set of genes common to both the U133A and the cDNA microarray (for 78 genes). The U133A-based cDNA classifier was then applied directly to the normalized and scaled Denmark test population.
-
In addition to identifying those patients for whom therapy is most beneficial, the classifier of the subject invention can identify those genes that are most biologically significant based on their frequency of appearance in the classification set. In one embodiment, those genes that are most biologically significant to colorectal cancer were identified using the classifier provided in Example 1. Specifically, osteopontin and neuregulin reported biological significance in the context of colorectal cancer.
-
Osteopontin, a secreted glycoprotein and ligand for CD44 and αvβ3, appears to have a number of biological functions associated with cellular adhesion, invasion, angiogenesis and apoptosis (see Fedarko NS et al., “Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer,” Clin Cancer Res, 7:4060-6 (2001); Yeatman T J and Chambers A F, “Osteopontin and colon cancer progression,” Clin Exp Metastasis, 20:85-90 (2003)). Using an oligonucleotide microarray platform, osteopontin was identified as a gene whose expression was strongly associated with colorectal cancer stage progression (Agrawal D et al., “Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling,” J Natl Cancer Inst, 94:513-21 (2002)). INSIG-2, one of the 43 core classifier genes provided in Example 1, was recently identified as an osteopontin signature gene, suggesting that an osteopontin pathway may be prominent in regulating colon cancer survival.
-
Similarly, neuregulin appeared to have biological significance in the context of colorectal cancer based on frequency of appearance in the classification set of the present invention. Neuregulin, a ligand for tyrosine kinase receptors (ERBB receptors), may have biological significance in the context of colorectal cancer where current data suggest a strong relationship between colon cancer growth and the ERBB family of receptors (Carraway K L, 3rd, et al., “Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases,” Nature, 387:512-6 (1997)). Neuregulin was recently identified as a prognostic gene whose expression correlated with bladder cancer recurrence (Dyrskjot L, et al., “Identifying distinct classes of bladder carcinoma using microarrays,” Nat Genet, 33:90-6 (2003)).
-
Accordingly, the identification of such genes may be significant in terms of gene therapy. For example, a therapeutic gene may be identified, which when reintroduced into tumor cells, may arrest or even prevent growth in cancer cells. Additionally, using the classifier of the present invention, a therapeutic gene may be identified that enables increased responsiveness to interventions such as radiation or chemotherapy.
|
Sequences | |
ACCESSION No. AA149253 |
ORIGIN |
1 | aatatggaca gggagtctca ttgtgtttat catatcaatt aatattacag tacatccttg | |
61 | gtaatacaaa attgtacacc ttcatcaaat aaattaggat aaattaaacc aataaattat |
121 | gcaaagtctt cagaacaata gacaacaaca aaaattcaca attgaaattg cctctagcta |
181 | aaaaaaacaa acaaaaatca aaaattgact ttatcagttc agttattgta ctatattcaa |
241 | atcaaagggt ctttattaca aaaaagagct taataatgct atttacaaca tattgctaaa |
301 | taatataaag gcagtgtttt gtcacggttt atactatata catatgagaa atggctggga |
361 | caatattgag ggaagcccat gaccttttgg attcttccag gtagcgctga gaccnatccc |
421 | aatacatttt ttttccttag ttccaaattt gganggcgta atatngcagt tttnagaaat |
481 | tttccncccc ccntttttag gggggattgg atattttana aaaattccgg atggaatacg |
541 | gtttccccna aggagggtag cntggtt |
|
ACCESSION No. AA775616 | |
ORIGIN |
1 | tttttacatt caagataaaa gatttattca caccacaaaa agataatcac aacaaaatat | |
61 | acactaactt aaaaaacaaa agattatagt gacataaaat gttatattct ctttttaagt |
121 | gggtaaaagt attttgtttg cgtctacata aatttctatt catgagagaa taacaaatat |
181 | taaaatacag tgatagtttg catttcttct atagaatgaa catagacata accctgaagc |
241 | ttttagttta cagggagttt ccatgaagcc acaaactaaa ctaattatca aacacatcag |
301 | ttatttccag actcaaatag atacacattc aaccaataaa ctgagaaaga agcatttcat |
361 | gttctctttc attttgctat aaagcatttt ttcttttgac taaatgcaaa gtgagagatt |
421 | gtattttttc tccttttaat tgacctcaga agatgcacta tctaattcat gagaaatacg |
481 | aaatttcagg tgtttatctt cttccttact tttggggtct acaccagcat atcttcatgg |
541 | ctg |
|
ACCESSION No. AA045075 | |
ORIGIN |
1 | ttttttnttt tttttttttt tttttttttt tccaggaaag acagatgtta tttaccacca | |
61 | atgaattttt atcatattta aatgaacttg aaaatgtcat tcaactcaaa tccctcaatc |
121 | aacttacttc agcccattct gaaacttcat attgcagcaa accagccatg tgaaagaaat |
181 | aaattcaat |
|
ACCESSION No. AA425320 | |
ORIGIN |
1 | ttttcaggtt gtaaatattt atatttctct cacatacaat gttgtatgag acacttgttt | |
61 | taatatgtat ccataggatt aatactcata tggagtataa tgtggaaaag tgcagaacta |
121 | aagaaataag tctatccgaa aacaaaagca cacatttctc aggatttaaa aatattgcac |
181 | atagtaaggt tgcacagaaa ttactggctg gttttacaaa cagaatgagg tatcagtcaa |
241 | tctctagata aagatgagag agaggataaa ctacacacac acaaacacat aaatccatac |
301 | taagacctaa gagtgccaac aactaagaaa gaaatatgaa aaagctatgt taggtagcca |
361 | ggatttcaac actacaaaat catttttagg ctggaaccaa acacataaca atctcttggc |
421 | aatatttcgt taagttttca acttttttcc agcctaaatg actatgggca ataaaaccat |
481 | ttcctttacc ccagttctac tgtagaaagg cacagcgctg tggtaaatat caaaccattc |
541 | ctttctcaac |
|
ACCESSION No. AA437223 | |
ORIGIN |
1 | tttggtgaat aaactaacag ctttattaat gaaggcaaac atcagatcat tgtatgaata | |
61 | ttatatatat atataaaaag aaatccaaac taacagcatt gtatttcaaa agtactgtac |
121 | ttctgtttct tttaaagaga cttgtcatct gtttttataa aacaaaatgg gtactcttct |
181 | cctaaaaaat cctggaaaaa tgaaatagtc aatttcaagc tgatgaattg aacacacctt |
241 | tctttaaatg cagactattg ctaggaagca aataaagtca agcatcagaa agaagatgta |
301 | tgagaaatgc atgaaagtca gagaaaaggg atgtagtgaa attactgcta atctttcccc |
361 | cctatattca aagaccatcc aaaactggtc tttcatacaa atataaaata actataaaga |
421 | gagggaattt gaaaccatac ccatctgaaa tc |
|
ACCESSION No. AA479270 | |
ORIGIN |
1 | ctctgaattc atttatttag aggtaaaaca cagccattca aaattgtgga atacaatgtc | |
61 | tacacacaga ataaggttgg ggaattaagc tgaattgtta tattccattc acattaataa |
121 | atatttttaa agaagaaatt gtagatttta aaagcttcat tagacactag tgacacatac |
181 | aaataactaa actctcatac tgcttgattt tcaggttgaa aggttacaat aatctatata |
241 | tttcaattac atggcagtaa atacaaaagc attttaaaca tcttttgaac tgtgtagtat |
301 | actataagca ggagttt |
|
ACCESSION No. AA486233 | |
ORIGIN |
1 | caaattgaat attttattaa catggtagtt gcctttgtaa catgtgcaca cacactcgca | |
61 | cactcagaat gatctgcctg ggggaaaaat actaaatatg cctaagggga aaatgaaaaa |
121 | taaaaaaatt cctgtaggtt ttcattattg taggcaatta tgtccacatc acttacaaag |
181 | ctattgccaa atctgtccaa ggaagcagag tttgaagtga gggctaggga caggaatctt |
241 | gggaaaaatt caacagtggc atagcagagc tctcaatatg agaaagctga cataatgtgg |
301 | acttttgctg tgaattacct ctttgcaaaa tatggggaga ggtttatcaa tgggcagaaa |
361 | ataagagaag gcggtgtgaa gtaggcttct gcagtcaatt ttcctcacag tattgtgcag |
421 | ggtcatcaag aaaatgctta gtctttctct ggaaccagtt tcagaacttt tccaattgca |
481 | atggtcttac cctcatctct taagggtgaa cgacccacct aagggaagtc tttaaag |
|
ACCESSION No. AA487274 | |
ORIGIN |
1 | tattactgca tatgttatat taaatttaca caatgatata taaaaacaca tactgtttat | |
61 | attatatagt aatttaacat caacaggagt atcaacacaa gtactactca tgcacaaaac |
121 | atgcatatat tggtatacaa aaagcaattt tacacaatac tgtttaccaa aaattttttc |
181 | ttaaaaaaca gcccttccac ataggatcaa aggtccaatc tggactggat tgcactaata |
241 | tgttcaggtc aacgcttcgg tggcatagcg ctcagtgagc aattctggga ttggagtcat |
301 | gcccaagggc tacttcatta atagtga |
|
ACCESSION No. AA488652 | |
ORIGIN |
1 | tttttttttt tttgcaacgc aagggctctt tattgtcagc gagacgagca ggccaaacgg | |
61 | gcactgaggc tccacggggc ccaggcctct ttccgtggaa gagaggcaag aggggtttca |
121 | ggattcagag gggtcctccg ctcacgcagc accatgcaaa tatagagcta aaaactttct |
181 | gaatgtctct ggcttgaaac caactgggcc aacaggttcc acaaccactc tctttttgat |
241 | cactgggaga caccaaaaat gctgatagag gagctggtct gagtccaccc aggccaaatt |
301 | cttgacaccc tcgttagagt ccaggtctgt ggtattcagt tgaaacacta ggaaatggaa |
361 | gacacgtcca tccgtgccca ggctctgcac caccacgggc tgctccaaga ccttggcatc |
421 | attcccatag aggagccggg cctgagcagg gcactgcaaa agcaaacagg atcatcttgg |
481 | cccgcagctg atctggttga aggcggtgtg gtcgtaaatt ggctttgtcc agtaagtaca |
541 | gggtatgggg ataggggtaa ggatag |
|
ACCESSION No. AA694500 | |
ORIGIN |
1 | tttgacagaa gaaacatttt taattgttct tgtcctgccc catcaccagg ggagtcccgg | |
61 | cattgctcag gctcactgcg cttgctttcc cctgggatgt cgaggacact ttgacctcat |
121 | ctatgtcata gcccatgtgt ttctcagatg ccaccgccat aagatctagt gccccctggt |
181 | gccattggga taggcaggcc agagaggcat gggagctggg tgtgcaccag gccacagggc |
241 | tgtggggcat gcagccgatg gtgcagcttc aggtggatgt gctgggtgaa gcgactccgg |
301 | cagacactgc actggaaggg ccgggtccgg aggtgca |
|
ACCESSION No. AA704270 | |
ORIGIN |
1 | ctaaatcaag tagtgctact gaaatccagt gcctaatgga gcagatggtg gaggtcttag | |
61 | actctggaac atttatagtg atgcttctga atgcaaaaca ccaagagtgg atttcacagg |
121 | ctgtgaatct gatttgattt tgatgggagt aaagcttcca ttttcactgt acttgaacca |
181 | caaaagaaaa aaagcatgtg tgactgacac aagctagtta agaaaaagga acatgttaaa |
241 | tattagtccc ataaagggaa gcagtttaaa caagtgatta tttgtttgta tcatttaaca |
301 | tgattatgtt tgtatacaat accaccgtttAA706226 |
|
ACCESSION No. AA709158 | |
ORIGIN |
1 | tttttttcct tcaactccct ccaagttgtt tatttaataa taataaaaaa gaaatgcaca | |
61 | cacataaacc tgaactcccc cccaccccac cctcccttac tcccagtaac tagctccaaa |
121 | atgaaaaaac ttcccttgtc ccacctgggg actaaattcc cacctccact gccataacac |
181 | tagagaaaca aaataaaaaa tatgcagcag ctcaccaccc accccacaac tgaacctcac |
241 | acaatcccct caaacaaaga agccaggact gggggttcac aggaatgaga ggagccctat |
301 | attctgaaaa gggatgagaa gagaggtgaa cacccccacc tcaaataagt gcttaacccc |
361 | cacacctgct ctttccttta ccaattgccc caagcctggg gaatcaggga aatttgaaac |
421 | agt |
|
ACCESSION No. AA775616 | |
ORIGIN |
1 | tttttacatt caagataaaa gatttattca caccacaaaa agataatcac aacaaaatat | |
61 | acactaactt aaaaaacaaa agattatagt gacataaaat gttatattct ctttttaagt |
121 | gggtaaaagt attttgtttg cgtctacata aatttctatt catgagagaa taacaaatat |
181 | taaaatacag tgatagtttg catttcttct atagaatgaa catagacata accctgaagc |
241 | ttttagttta cagggagttt ccatgaagcc acaaactaaa ctaattatca aacacatcag |
301 | ttatttccag actcaaatag atacacattc aaccaataaa ctgagaaaga agcatttcat |
361 | gttctctttc attttgctat aaagcatttt ttcttttgac taaatgcaaa gtgagagatt |
421 | gtattttttc tccttttaat tgacctcaga agatgcacta tctaattcat gagaaatacg |
481 | aaatttcagg tgtttatctt cttccttact tttggggtct acaccagcat atcttcatgg |
541 | ctg |
|
ACCESSION No. AA777892 | |
ORIGIN |
1 | cagcttgcat cataagtttt attcccgatg cgggacagat ctttccatcc ctcaaatgta | |
61 | ttacatgtcg ccacggaagg gcttaggatg ctgctcccat ctccaggaaa gatgagaaaa |
121 | aggtacagac tgggagccag tccaggacca ttctgcagtt cctggctctc ttaccctccc |
181 | ttctcagcag aggaattatc tctcatccat tcagttaaaa agaaaaaaaa aaaaatcatt |
241 | aacaaaacaa aacacacctt aagtattggg caggggtgtt cttgtcctca gtaggacgtc |
301 | aagttctggg tcaccaatgg tgattttttt tgtttttgtt ttttgtcatt tttgtttgtt |
361 | attttttttt tttnnatttg ttagttatgg ntagcagttg tgtgtccacc tcatctgcag |
421 | gcagctgcac atagcggacg actgagcccc tgatgaagca gttcttgact gataacatgt |
481 | gagggtattt ctcagggtct gtgacactga tgtcggttag tttgatattg aggtactggt |
541 | ccacagagtg gagggttcca cagatgctca ggtcattctt gagttccacg actacatacc |
601 | ttgccacaag agacttgaaa aaggagtaga agagcat |
|
ACCESSION No. AA873159 | |
ORIGIN |
1 | tttctgtagg atttttattg gtggcacctg gggccacatg gagggagtcc tcagcacagg | |
61 | cgctggggtg tgggaaattt cagaggcccc tcctgggatg tcacccttca ggtcctcatg |
121 | agtcaatctt gagtttctcc ttcactttct gaaatggctc tggaaaacca ctcccgcatc |
181 | ttggcagaaa gttcactctg tttgatgcgg ctgatgagtt cccgagcctt gtcctccagt |
241 | gtgtttccaa actccttcag cttatccaag gcactggaga cgtctggggt cccctgggct |
301 | ggggctgggc cttccaagac gatcgacaga accaccacca ggaccgggag cgacaggaag |
|
ACCESSION No. AA969508 | |
ORIGIN |
1 | tttttttttt ttttttcact tcttcaacaa gtatttattg aacgccaact atggaccagg | |
61 | ccctgtgctc aatgctgggt acagagtgga gactgaacca ggcatggcac ctggcctcat |
121 | gagcttacac tcgagtggga ggcacagtca accaacaagt aaattacaca aatggatatg |
181 | cagtggcaaa ttctccatga agggaaagaa cagaggcctt gtgatagagg aactccacaa |
241 | gtaaagtagt cgaggaaggc ctcttggacg aggcaacgtt gaagccaagg cctgagggtc |
301 | tgcagaactc agccatgcac agggtagggg aagagcattc ttggcaaagg gaacagcata |
361 | tgcaaagtg |
|
ACCESSION No. AI203139 | |
ORIGIN |
1 | ttttttgagt ttggcatgtt aatttttatc agcgacttct ggggcctagc accattcccg | |
61 | gaagaaggga gttgtcgggc agggtcctta atgggggttg caattcttgt cttggttggg |
121 | aaagagccta gctgggaaca ggggtcgttt gtgtagtaac tgtattaagc |
|
ACCESSION No. AI299969 | |
ORIGIN |
1 | gcggccgcgc cggctccagg gccatttagc ccccaggagg agaatcgagc aatctttttg | |
61 | gaagtccaga agaagctact ccttccagca ggcctaatag gatggcatct aatatttttg |
121 | gaccaacaga agaacctcag aacataccca agaggacaaa tcccccaggg ggtaaaggaa |
181 | gtggtatctt tgacgaatca acccccgtgc agactcgaca gcacctgaac ccacctggag |
241 | ggaagaccag cgacattttt gggtctccgg tcactgccac ttcacgcttg gcacacccaa |
301 | acaaacccaa ggatcatgtt ttcttatgtg aaggagaaga accaaaatcg gatcttaaag |
361 | ctgcaaggag catcccggct ggagcagagc caggtgagaa aggcagcgcc agaaaagcag |
421 | gccccgccaa ggagcag |
|
ACCESSION No. H17364 | |
ORIGIN |
1 | tttttacttg aaattaaatt tggnctctaa agttggtgta gcagcagttg atcagnactg | |
61 | aaaaacggtt tttagtctcg gaaaaagact gattttgctt ttttataaat attattagat |
121 | ttattaattt ttcgtgctca atgtgtaaat tgtattataa ttcattgtga tttatttcac |
181 | ttttaatttg ctggtgtttt aataaatggg ggtgttactg aatctttctt cccacttcca |
241 | tttcttttga ccacccctta accctcaact gtgacggtag tagtattatc atttatacca |
301 | aagttttgca tagtccctgt tgactttgta atgttaacgg agtcataaaa gcactaggca |
361 | agagaaagat agaaatttgc ttttaatctt tttgcctttt attttgcaca ttatgcaaaa |
421 | gggaaaacat taaaggacac tttttttaag ngagtgaaac atgggnaagg catccagtgc |
481 | tttatgcaca ttgtnagcta atcaggccat tat |
|
ACCESSION No. H17627 | |
ORIGIN |
1 | tttttttttg ggcagatgag aaacagaatt atcatcagag tcttgctaca aacagggaaa | |
61 | aacacaaacc aagatgacac acggacatgg tagattaaac attcctcccc accttcagga |
121 | tacatttaca ttgnaataaa tactgcaatc tcagcagcgg caaacaagga ggaatntagg |
181 | aaatgcccac ctcctcccct ctgtcttatc tgtgtgctct cttccttggg tagcaccgat |
241 | ctccccaggg tgctgggtga gaaacaggac aggggngaag aggtccgtgc atgctcactt |
301 | gcccttttgc |
|
ACCESSION No. H19822 | |
ORIGIN |
1 | gaagtcatan tatgataaac attttattac actaaaaaag tcatctgtta actgactgaa | |
61 | ctgcaggggg accacatgtg aggttacttc agaaaaatgg catcagataa catatataga |
121 | tttctggcat tataaaatgg ctagattctc ccctaccttc cctcattaaa tattaatcag |
181 | tggcttaggt cagttctagt gggaacactt aattgctgac ttcacataaa accaggntta |
241 | gcctaatgtg ccaatggtat gagtccattc ctgggccatn ttcccaacag ccagaccgct |
301 | gtggcttgga caccggaggc aacatctggg gggcctcagt tccactcctc tgtggtnagc |
361 | ttgctttccc aataactggc tntggagtca catcaacaat ggtggc attn catctggggn |
421 | ccacatgagc cctttggggg tgctgcatcc ctactng |
|
ACCESSION No. H23551 | |
ORIGIN |
1 | ttttttttta tgcacactaa ggnatatttt attgtggcat taattagatg aaagttagta | |
61 | atatgncatt gaccaaaaca tttgattgac aagnaccata aaggttaact gagagttttc |
121 | tttaatataa ttgttgtaca gacaaggatt cctgctgtat agagtatata gaaggatgac |
181 | atactctagg aattaggaac aatatatatt caatacaata acaaaactat atagtacttt |
241 | aagaactctt tcacatatat gaacactctt acttaggaac ttcagctgtt taaagtaagc |
301 | aatatgcaaa cctataaagt acacaccaaa aaaatctaac ctacaaaaca cccaaagcaa |
361 | atgttagcat atctctatta tcaagaatat cttctcacca tcgtttcttt caaaaatatg |
421 | tgaaaaagtt ctttctttcc ttatgagtgg caatttttaa aggcccctct tctgaaatta |
481 | gntatgttcc aatccactat cactcttaag ggaaaatgga acdnctctgg g |
|
ACCESSION No. H62801 | |
ORIGIN |
1 | aatgatatca gaacctttta aatgatctag tatctgtgat gttagcgccc ttgggattca | |
61 | gaaagtggtg tgcatagtaa aagctttcat tgtaactcac cctgcctaga tatgcagaaa |
121 | gcaaattcag tgataagatc tttcctggga gaccaatcag cagcctcagg ctctgttggg |
181 | gtctatcaca atgatgttat ctaaatttag ggcaaggaac cctttcccca tcttttagag |
241 | ggcagtgagt gttctaatca cttcaagata ggtatctgat aaaagtcttg gggccaactt |
301 | tttcatactt aggnagggca caactaaaat ggatatactt aaaatggtat caaaggaggg |
361 | ttaggtgtac actctactag gtgtaaggtn tatttcatta caaaatggct ttgg |
|
ACCESSION No. H85015 | |
ORIGIN |
1 | cacccaggct acagtgcagt agagcaatca caactcactg cagcctcaac ctccctgggn | |
61 | ncatgcaatc ctcccacctc agcctcgcaa gtagctcgga ccatggccac acgccaccac |
121 | acccggccaa ctttcgtact tcttgcagag agagggattt gccatgttgc ccaggccggt |
181 | cttgaatttc cgggctcgag tgatccactc acctcagcct cccaaagtac tgtgattaca |
241 | ggcatgagnc actntgccca gccaataaan tcttt |
|
ACCESSION No. N21630 | |
ORIGIN |
1 | gaacagacta aatttgtttt aacaatccca tttacaattc aaattccttt aaacaactta | |
61 | atagcattta tacatttaaa aaaatgattc ttttaagcag cattgcaaat gcttgacccc |
121 | attagcataa accttcccaa gtgcttaact ctcataaaca taataaatta aacatatggt |
181 | gactttccaa gttctctgaa acatttcagt acttttgcag acttagtaac attttaaaat |
241 | acctttcaac tgaaactcat aagtctaaaa gtctgttaag cattttaaat tagaatctta |
301 | aggccagtgt cacatattgt aatatgccaa ttatgtttaa atacttcaaa cagcaaatac |
361 | tacagtttat ctcaatgaat ataataacca ttcctgctgg gcgcagtggc tcatgccttt |
421 | aatcccagtc attaaggagg ctgaggtggg aagattgctt gaaaccagga gattgcctca |
481 | ggcctgggca acatggtgag acctcctatc tcaaaaatcn aaataaaaat tagctgggca |
541 | ggtggctcat cctgtagccc agcntctcag gaggctgagg tgggaggata gcctcgccta |
601 | ggagacggag ctgcagtgag c |
|
ACCESSION No. N36176 | |
ORIGIN |
1 | aataaagaca agtgttcaga tttatttgga aattcacagt ttctaatggc actacagctc | |
61 | cgtagttaca tattgaaaat tctcttccca caacacacag atcacataat ttctcactgt |
121 | atctctgctc tcatctggac ctcttttcaa ggggcttcta taaaatcagg ncctcttgnt |
181 | cngganagnn nantngngcn gacaggaaag aaatttaaat cttctaaaac acgctgttaa |
241 | cctaaagcag caacttaaac aaacaaaaaa ggcgttaaat aagtcacatt acaaacaata |
301 | cccaagaaag gtattaggca agtttaaaaa cagttatcac tactaaaagt gctcaataag |
361 | ttataactta aacatcacaa caataaatgg tcaattctct ccctttcaaa aagaaacatg |
421 | ttccactttc attcactact gtacaatcat acta |
|
ACCESSION No. N72847 | |
ORIGIN |
1 | attgttactc tagttttaat ggtttcacaa atacaaaagt tgctagataa gcagtaccaa | |
61 | catatctaaa tctccaatga tgttcaatta aaattttatt tatagactca tacactcagc |
121 | aaaaccactc atttaataag tccaactgaa ataaattctt attaataaaa tacctatatt |
181 | gaaagtaata tattgtaaga actctacctt aaattgacca tggggatgaa ctacaatgtc |
241 | ataaaatatg agccaaaatg ttcactcaat aattttaatt acatcacaat taagcccaga |
301 | actatgcctt ttttttggtg taaggctgaa taaggaccga aactggatgg agagaaaatt |
361 | gctttctaaa gcctcattta ctggcaataa cttaccttat gcaataacca acatcacgng |
421 | actgg |
|
ACCESSION No. N92519 | |
ORIGIN |
1 | ttttttttaa ctcttaaaaa aaatcatttt attgatcctt taccatacaa aatttattca | |
61 | aattacaccc atttgaagtg gtaagatcac agctagagaa caggtcaccc tgtaacaaat |
121 | ctatttacaa aatccatcat aaaagctttt ttttgttttt ttttacatta tattacatat |
181 | tttctttttt aaaagcatac aacacaaagc taaactgatt agtagtttgc ctactcccaa |
241 | ttttgggaga aatacttcct ttttacaaaa tcacgtnccc cgtaggaaaa gaaattccca |
301 | caccctgaca attggccaac cgacttactc tgcaagccat cttcttcaaa tccctccttc |
361 | tcatacacac gangttgtca tgcacacact gaatcntaat ttcttttccn ggaagcttaa |
421 | ncctttaaat accgggaatt attttcagat ctncacgtnc caacaaaaat ggaaacaagg |
481 | gccccaccaa gnccgggaaa acnaaaccca ataccctntt aaaaatttca aggc |
|
ACCESSION No. R27767 | |
ORIGIN |
1 | tttttancna tttgtaaata agtttaattt ttnagttttt caatgacatt cagtagagat | |
61 | agttatattg gctatataac acaagtaaag tggtgtttgg aaagtggagg actaggtttt |
121 | ggcacggggc taggacgggg tgaccgccgc ctcaccacca cagactggag ggggcttttg |
181 | agagctgggc ttcgctcccg aggactcagc tcagaaactg ctgaggcccg tgatgcagaa |
241 | ccagtgccgt aggtgggcat ctggccatgg cttcgagctc tcaggatgct tttgtatctt |
301 | gagagggtgc ctccagagaa tgtctgctcc ttgggcctca tctncccggg ttatnccccg |
361 | gcag |
|
ACCESSION No. R34578 | |
ORIGIN |
1 | atttttgaag nngnttcgat gtcttactgt tatgaccata aaaccaataa agctactttg | |
61 | aaaagttaaa gccaggngta attaaacaac tcatacttga ttgttaaagt cagtctctna |
121 | aaagtgtaat tttaaaaagg taataaaaaa ggtatancat tat |
|
ACCESSION No. R38360 | |
ORIGIN |
1 | tttttttttt ttcaaaaatg tcaaacttta ttcaagtgtt atggtaagaa atttgaaatt | |
61 | cttaggtaag ctantgaata aatccttggg caggtgcagg catacagatt ctggggtgca |
121 | gctgctgagt ttaaaagctt cctttggaga tgccccgnng gggnnacacc ccctntcccg |
181 | cctntcaaga ggaggccatc ctggggcagc acgttagggg caaatggccc agatgcccag |
241 | ctnagggaaa cctccatgcc tagaggagga ggtcgctctg ggagcaggag gaccttcttg |
301 | gaacccctgt tnacaggntc ctttttcttg ntttttccag nacctcctgc aggg |
|
ACCESSION No. R43597 | |
ORIGIN |
1 | tttttttttt ttttttcagg attcactgcc tggggtatcc cactatatat atctcaccta | |
61 | tgatgtagtg gtgcttgaaa tactcatctc attagctcga ttttattatt ctaatctaag |
121 | gttttttata ttattcatac tatgatattt ttagggacaa tcagtaatat ttggggcaga |
181 | gtactgaggg acctcttgaa gtctgcaaca gcatgcattt tctttgtttt tgtggggagt |
241 | gcttccctgt aggctgtctt tgttctagga acactgnctc caaatttatt tccatgggga |
301 | tgtagggggc tagtaggccc atggtggaaa ggtcttctgt aaatctccnt gggggggtnt |
361 | gagttattgg gggttatttc taacagggan ttttcccaaa ggggg |
|
ACCESSION No. R43684 | |
ORIGIN |
1 | tttttttttt ttttcattca aaaatatata atttattgag tacttgctag acacaatgga | |
61 | tacaatgatt atatagtccc aatcctccag gagaacaata gacagacacc tttataatat |
121 | gtatgtggag tgctctgaca gggaaaagca caaggtccat gggggtggga gtggcccagn |
181 | agctaaggaa ctcttccccc atgaagtggt tacttacttt ctaatcttta atttaggatt |
241 | ctctcatgga acatttgant ggtgaaattt tactacataa aggttctcaa ccctaggagg |
301 | tttatccctg cccccctggg aacatttggn caatgtctga acaacaagtt tattntcaca |
361 | actggggagg ggngaaggaa gttagcagag gccaaggatg nctggctaaa ccttaaattc |
421 | ctacat |
|
ACCESSION No. W73732 | |
ORIGIN |
1 | tatttcaaaa aaagtctttt aattgttcaa aatagcacaa aacgacatcg cactatggta | |
61 | atattgagtc acaggggtta cnctacaata gtgaacggng tactcncctc agaaacaaat |
121 | cant |
|
ACCESSION No. AA450205 | |
ORIGIN |
1 | tttttgtttt ctttcattat ctttatttta aatttgatat tttagaatag gaaattatct | |
61 | ttcacagcaa tgcctcctgg tctgataata cagtatctca tttctgaatg taaagattta |
121 | aaataaatca aaatgaacat taaggcgtac aaagctactt taagtctgct cttaagatca |
181 | gtttttgctc atattcaaaa tacatggaat gttggcacaa aactgaagct gctgtagaaa |
241 | gatcacagat gttctgtggg ttactcaaac ttccatttct ctaaaaacat acccttacat |
301 | ggtcttaatt ttatgaattt aagtgttgag aaatatctaa ataataagta acaattaaaa |
361 | taaaatgttt tatttgtaaa ttatgtacag aatacacttt acgttacgc |
|
ACCESSION No. AI081269 | |
ORIGIN |
1 | tttttttttt ttctaaaact acctttattg tggttggctc gacataagat gccgccatca | |
61 | gcagaattat aaaactgtac aggaggcaca aaaataggct gtttaactta gataatgacc |
121 | ctcatgtctt caagctttaa aaatgcacat aaaagttgta caatctggca gtttataaaa |
181 | tataaagcta aaaagaggat tttgggttcc acaaagaaga ctgtatcaca caattaacac |
241 | gtactaatta aacaattaac catccacaca gaagacataa tg |
|
ACCESSION No. R59314 | |
ORIGIN |
1 | tttttttttt ttttcaaaaa ctttattctt ttctaataaa aatgatatat gttcattata | |
61 | aaaagtttca aacacacatg agtctganga ntgtaaagat cacccaaata ccacagccca |
121 | gaaaaaaaaa tccttaacat ttggtganga tctctctatg aaacatacat tatcttaaaa |
181 | tattcaatgt tataaatgag ctcatattca acatatatcc tgtngtctac tttttgattc |
241 | aataatattt tgggaacata tatccatngc antaaacata tatctaaata tttttaaatg |
301 | acaactggca tgggnnttta tttaatccat cttttactga gggatgtttc agttgtttcc |
361 | aatgttttaa tatcataaac atcatggaaa tataccnttg gggctccatg tttgganggc |
421 | ttggggcaac ctt |
|
ACCESSION No. AA702174 | |
ORIGIN |
1 | catcttcagc attaagaagt gctgacacaa tatcattaac tgttttatag ttctctccag | |
61 | ttgtcaggat tttactttga actgtttgtt tcaccaggtc tctattaaag cccatttcca |
121 | aggcagattt aaccacaggt gtattcatca tgacagcatc ttctgaagaa ctttctccag |
181 | gtccaaaatg aataattggt gggtcagcat tttcttctcc agtggtatct gaagttgaca |
241 | acagctgttc aagaagatga ggatatctac cttgaatctc atcaacaaac tcttggcctt |
301 | tcattcgtat caagaactca caccttggaa accacttggc atgttctacc catggatcat |
361 | ctccagattc ccaacacctc aagccaccat cacaacaaaa gcatttgaca tcatcattgc |
421 | gacccacata ataaaaacca gcacttgcaa gctgctcagg ctgaactgga acactagatg |
481 | gccagtacat aaatgttctc attcgagctg catgtgtctg catgctcaga tttgaaatgc |
541 | taaacctcag agtttctaga gaa |
|
ACCESSION No. AI002566 | |
ORIGIN |
1 | tttttttttt tttttttttt tttttttttt ttttcacaat tcttaagtct tgttaagaaa | |
61 | gtaaaaaacg tttgggtata ttttgatcca tgggtggcat tttcaaatgt gcaaaaacaa |
121 | agtcttggaa gagattcctt gtcactagaa agttcgccct tccttttgct gtcagttgta |
181 | cgtaagagaa attcgtccac attaaggaat ccaaaaaggg taaactaaag ggatttaaaa |
241 | agagtacatt acaaagaata agaagccctg taacatctat ctgagaatac tagataaatc |
301 | tgtgagtaga tgtggcacct ggagctactc actacattac taaaaacaga aacaagaaat |
361 | ctataatggc aggatcacaa catttgcgcg caaatagcta acc |
|
ACCESSION No. AA676797 | |
ORIGIN |
1 | aataccttct gttttaagtt tttcttttgt tttcatcttg gaaaaaagga aatttagaaa | |
61 | taagacagga aaagaatggc ccagaaattc agcacaaaga gaggtgtaca cattgacgcc |
121 | atctgtgggt cacatacgaa cgcctctggg acagagctct aaaacgagtc acgtgtcgta |
181 | gggagtgggc ctgtggcaag gcagtcctcg cagtgtgcag ggacgcaggc ccccttacca |
241 | tggaagcccc acccagaagg aagtgggtgc cccatgcagg ccgaggtgga tgaggggaca |
301 | gtggtgtgct cacagctgtc agctccccac tgaagcccca aaccagcaga tgtgggcagg |
361 | ggctcaagtg gtgtctgact acccaggtca cacgtgcctt aagcgtgaaa gctgtcagct |
421 | cccggcacgg gctctggtgg ggctgggaac accaggacac acatgggctg aagcttccag |
481 | agacagtgag acacggaagg gacagagagg tgccctccac acagtgtg |
|
ACCESSION No. AA453508 | |
ORIGIN |
1 | tttggttatt cagtatttat tctgcaatgc aaaggtgaca aactaaaata taaaaaggct | |
61 | gttatggctt aacatttttg ttgcagatta aatatgcagc attgaaaaat ggaaaggcgt |
121 | ggcttcatct ctgaccagca gagttaaaaa gaaaaatctc tccattttcc ttcatcatca |
181 | tgggatacac tgttcaggca atccaaatta ataaagactt gcactttcat atgaacacaa |
241 | gatcaagtgt accagttagg ttttcacatt cacagtatat aagaaaatac acatggaagg |
301 | aaaagtaaag ggttaact |
|
ACCESSION No. W93980 | |
ORIGIN |
1 | tgaatgaggc aacaaaagca gagatttatt gaaaatgaag gtacacttca cagggtggga | |
61 | gtggcttgag caagtggttc aagagcctgg ttaccgaatt ttttgggggt taaatatcct |
121 | ctagaggttt cccattggtt acttgatgta cacccttgta aatgaagtag tgcccacaat |
181 | cagtctgatt ggttgaggga ggggacctat cagaggctga agcaagtttc aaagttacac |
241 | cctatgcaaa tctctgattg attgggaaaa ggctgaagtg aagttacaaa gttatactcc |
301 | tatgcaaatg aagacttggg cccatgacca gcctcattgg gttgtggaaa gggaccaatc |
361 | agaggtactt tcaatttttc catctaccat gcagaaaaag gttcgggggt ggggggttgc |
421 | caaagggaag ttagccnaac aaactcctga cctaccaaca gagggtccca gttgggtagg |
481 | ggggcctggg |
|
ACCESSION No. AA045308 | |
ORIGIN |
1 | ctattaatca acacttttta atgtagtaca tatatatctt acagttattt aagtcaaata | |
61 | tgtaaaggtt tacaactgat ttacagatga agcaatcaca gattgcagta atatgtgtgt |
121 | gtgtatatat atatttatnc catatataca cacacgccaa tcaaggggaa aactgcatcc |
181 | tggcaatttt acagtctgaa gttttgttgg tatatctacc atttcacatc cttttcatct |
241 | tgcttttctg tacaaaagat atttttngcc ttcttcattc ctgatgagat ttttctgcga |
301 | taactttaca ttcgtacatt gccagttgtc gaccaatgtt tcccattgtt atgcctccag |
361 | caaaaaatat |
|
ACCESSION No. AA953396 | |
ORIGIN |
1 | atctgtcagt aaattacatg tatcctggct gtttatttca aaaatgcttc agtatgtatt | |
61 | tcctaaaata gggatattct cctttgtaat cacagcaggg tagatactgc tctttagttg |
121 | tcatgtctct tagccttctt taatgtggaa cacgtccaca ccctttcttt atcttctgtc |
181 | ttttaaacat cttttctgtt gtccaatttt taacaacaaa gatgttaaaa atcagaaaac |
241 | tcagaaaagc acatggtgta ttaaaattcc acctaggaat aactgccatt aaagttttgg |
301 | tgtctccctt tctgtctctt cagatgcaac ttactagtct agacaaagca ggtttctcag |
361 | tgaataaaac at |
|
ACCESSION No. AA962236 | |
ORIGIN |
1 | ctaatcctgc gaatatgggt agtgcttcgt tccatggacg ttacgccccg ggagtctctc | |
61 | agtatcttgg tagtggctgg gtccggtggg cataccactg agatcctgag gctgcttggg |
121 | agcttgtcca atgcctactc acctagacat tatgtcattg ctgacactga tgaaatgagt |
181 | gccaataaaa taaattcttt tgaactagat cgagctgata gagaccctag taacatgtat |
241 | accaaatact acattcaccg aattccaaga agccgggagg ttcagcagtc ctggccctcc |
301 | accgttttca ccaccttgca ctccatgtgg ctctcctttc ccctaattca cagggtgaag |
361 | ccagatttgg tgttgtgtaa cggaccagga a |
|
ACCESSION No. AA418726 | |
ORIGIN |
1 | tttgagtttc aaaggattta tttgatttcc ccacatgatc acaaccatgg ttttacattg | |
61 | atagagtctg ttgccactga caaacagaat gcagatgaaa acaaacgcac tcctttcctc |
121 | tcaaaggtac acagtggggg tgccaggctt cttgtgaggg aggtgtcctt gaagtctctg |
181 | aacagtctgg ggattcagga cctgattcta attgcttaaa acaactcgga ggcaaaagat |
241 | attttccaag aggagatgca tgctgtgtgc agtctcgatg tgactgcaca cagaa |
|
ACCESSION No. R43713 | |
ORIGIN |
1 | tttttttttg atgtgctaat tttatttttc taatacttac caaaataaat gccaccactt | |
61 | aacatagaaa aaattgttcc catgtgacct aaaatcattc ctcagtcacc cctgaactgg |
121 | ctagtagcga gcatatgtgg agcggtggtg agggcaggat agcctggtta taggaaacct |
181 | cagantagga aagacctggg ttcaaatccc cactctgcca cttactagnc tgtgtgactt |
241 | tgggacaagt tgtgaaacct ctctgaggat ttatttcttc atgtaaaatg tcaccgataa |
301 | tggataactc agtgggtgta agantgatct attttaagga ttctagggca gagtcccngg |
361 | gcagggcagt taaggcactt aaataggatg gacaguctat tcattnaatt attaggcagt |
421 | tttttcctta atggagggtc cttgttggaa ggaccccttt tttcttaacc tcc |
|
ACCESSION No. AA664240 | |
ORIGIN |
1 | tgtgataggg ttccactttt tctctcatac tggtgtgcag ttgctgattc atggctcact | |
61 | gcatcttcag tctcccatgt taaaggaatc ctttcacctc agcctactga gtgtgcacca |
121 | ccaggtccag ctaattgttt ttttaacttt tttttttttt tttttttctt ggtagagaca |
181 | gggtcccctc tgttgcccag gatggtttgg aactcctggg ctcaagcaat cctcccactt |
241 | tggcttccca aagtgctgag attacaggca tgagcactat gcccaacctg agcaggatga |
301 | cttaaacctg atcaattcta ctccaaaaca gcaactatca ttaagtcagg ggtgtcaagg |
361 | aggactctgt gaaggcaaag actagactgg gatgtgtgcg agagtgggat aagaaggccc |
421 | atccctagca gactg |
|
ACCESSION No. AA477404 | |
ORIGIN |
1 | ggaaaacaaa aggaaaactt atttattctt agaggtggga atgtggggag tggggcagaa | |
61 | caggtggtgg ccctgggaga gggtcccaag gggcagaggt tggggatgtc tcagtaaaga |
121 | ggggcaggtc atgaatagag cctccacccc cagcaggggt tccttgggcc cgcccaagca |
181 | ctgggctaaa acgtggaaac tgggcattga caaagtacag cgg |
|
ACCESSION No. AA826237 | |
ORIGIN |
1 | aaagatgaga accagaatgc ttatatttta ttagtatcca agactgggga gagggatggg | |
61 | gtgggagaga tcaagaattg gggagcagat gggaggcgct acctcactca ggagacacga |
121 | gttcttatcc aagttcaagg tgaaagaagt gagggcagga agagaaatct ccctgctagc |
181 | aacagcgact cagggagaaa ctctgggccc atagctagct ggaggcaggg tgacattgct |
241 | cccaccaatg ggccatcttc ttagctacac ctttgtagct gtggtgccag gcagaagaac |
301 | cacctggaaa ctgagctaag gcaggttcct tcttccaaca gaagacacag ctgggcaggg |
361 | actgtgcaga ctcaacaggg ccaggccagc tagtggcang tcagtgttca tgtctctcac |
421 | cagtgcctgg agggtcccca gccaaggaaa gaactggtca gttcctgc |
|
ACCESSION No. AA007421 | |
ORIGIN |
1 | gtttgtagca gttccaaaaa gaaagcagaa ctcatttagc aattgtgata aaagaaggaa | |
61 | aaatgcatat gttttaaaag tcattaacgc atcgtgaaag cgctcccaat caacctcatt |
121 | ccctaggatt ttcagctaac taacaatagt gtctttttaa tttgatgtca tgaaaatctg |
181 | gtcacagcaa acacaatgtt ttctaaagca gatctggcct ccgagggagg aaagctctcc |
241 | agggcctcca gtgccttgtt tccatggtaa cgacacaggt caatagctga agtcacacct |
301 | ttgccagctt tgattctttc tcgcaactgg gagtctgagg caagaggatc acttgagccc |
361 | aggagtggga ggctgcagta agctatgatt gtgacactgc actccagcct gagcgacaga |
421 | gcgagaccct atctcttagc atagtccaat cttccttttt cttgag |
|
ACCESSION No. AA478952 | |
ORIGIN |
1 | tttcccagcc ctcaggccac tttattgctc aagagtggtc agtctggggt atctgcatgc | |
61 | ctgaactcca tgatgatgtc gcctgtgtcg gggtgaaact ccactgcata gctgacagtc |
121 | cgtgggccac ccagcagtgc tctgggatct ggggcagggc tgaagaagta gacggcctgc |
181 | ttgcagtggg ggttccagca gcagcccccc tcgggatctg caggctccag gaggccagtg |
241 | ctgagcgtgc actccggggt caggtggtac tccatccata gcaccgctgc gtggctctgc |
301 | acgggccttc tgagctccac ggtgccctcg gcacacaggg gctgcagggg ca |
|
ACCESSION No. AA885096 | |
ORIGIN |
1 | gtctgtgact cttggttagg gcaaatttca aatccattat aatacataca ttgcagcaac | |
61 | actgagtttc ttataatagg tactatccaa agctttcttt tttttacatg tatcacttaa |
121 | tcctcacaac cacctgagga ttaataccat ttacctgttt tacagataag gaaaacaatc |
181 | atttttcaat tatgactatg cccccaaaca ctggtttgga tggagccttc actggtatag |
241 | agaatgacct tcttccctta gactagactc tggctataat aaaggatggt ttaatcatcc |
301 | cctgaagcaa tgcataagat aatctgcaat gtatcttcac atactgtacc ttatttgata |
361 | ggcaagagac ccataaagga agctgagcat ggattatcag cttcatcaca aatctgaaga |
421 | aactgacatt tatgttatgt tgccttaccc aagttgggac atcagagcag caac |
|
ACCESSION No. H29032 | |
ORIGIN |
1 | tttttttttt tctataaatc tctaatgtta tttaggtttt ttaaggutt ggaagtaaca | |
61 | gagggataca tacagcaaga tccacttaca tagttttaaa acatgcaaaa caagattata |
121 | tatcgtccat atgtaattat atctgtggta aaatataaag atatgcattt tggggacata |
181 | gtcaccagat tattagtagc tcaaggaaag gcaggaggaa gagtgctctg ggtgggggga |
241 | ggttcacagg gtgcttggac tgtacctatg atttcttcaa ataaaaattt caagcaagta |
301 | taaaatatgg gatataggaa tgtaaaggat ttgggcaaag ctgggctggg tgggtatcca |
361 | atgttcctta tcaccatctc tgtacttctc tgantgcttt aaataggtca caatcnttgt |
421 | aag |
|
ACCESSION No. R10545 | |
ORIGIN |
1 | tagaatgaat tgcagaggaa agttttatga atatggtgat gagttagtaa aagtggccat | |
61 | tattgggctt attctctgct ttatagttgt gaaatganga gtaaaancaa ttngtttgac |
121 | tattttaaaa ttatattaga ccttaagctn ttttagcaag c |
|
ACCESSION No. AA448641 | |
ORIGIN |
1 | agccttagga atggttttta ttcacttgaa cactgtacaa atattacaat ttccttttgc | |
61 | tgcaaaaagt ataaaaataa tctttatata ggaatccatt cgttactgta aatctttcta |
121 | aatctctgca aatggcccta aatgagggta aatgaaaaag ccgaaatgaa gagagggtta |
181 | tggggcagca ggaggtgggg ccaatcatca gggctggacc acccagactc ctccccagag |
241 | acctctgttc cttcttggta gccgccccca ccacctgcag gttctagggc taaaggccca |
301 | gcagaagtgg gcacgtgaga gggccaggag gagctggagg gtcagggggt gggggatagc |
361 | gaaggaagct agaagtggtg ctggcatgtg cccagttcca ccccacca |
|
ACCESSION No. R38266 | |
ORIGIN |
1 | tttttttttt atcttttaaa tgggatttat ttatgtttac ataaaaggta gcaaatgtta | |
61 | cataagttgt ttccttaaga acatttattt tgtacaatca cattgttatc aagcaagact |
121 | tatggaaaat ttcctgggtc cacaacactg aactttgaaa ctactgtagc attctctttt |
181 | ccaagtttaa acatgacttt gtgcactgaa gaagtatggc ttcgcattgc acagtgggtc |
241 | acatgtgaca acctgacacc aagcgagaag ccttttgatg aaggaatgtt ttatcttttg |
301 | ttgaggttac caaaatgggg actttcatgt gtggtggatt atccaaaccc catanttttt |
361 | ttttncggtt ccatttctgg cttccaattn aaattaaccc ggtttaaact aggcnggttt |
421 | nggccaatgn ta |
|
ACCESSION No. H17543 | |
ORIGIN |
1 | tttttttttt tttaacctct tgctcatttt tattccagaa cctaggaaga actagtacac | |
61 | tgaaggcatt tgatgtttgt tatgaaaagg aaacaacaaa aaaatcaagt tcaggctggg |
121 | catggtgcct catacccgta atcccaagca ctttgggagg ctgaggcagg agggatgctt |
181 | gagcccaggg agtttgagat cagcctaggc cacatattca gaccccattg ctaccaaaaa |
241 | atttttaaat taaaaaatgg ctaggcatgg tgggcataca actgtaattc aagctacttg |
301 | aggaggctga ggtggggagg atcacttgaa cccggggggt tgagggccac agcgagctgt |
361 | gattcacaac actacactcc accctggggc gacgaagcaa gatttcgttt tcaaaaaaca |
421 | atttttgttt caantcccat cttcaccnta aaaacctngc tacattcccc aggggaaaac |
481 | caattttca |
|
ACCESSION No. T81317 | |
ORIGIN |
1 | taaagnnatg aggtcttgct ctgtcaccca ggctggagtg cagtggcaat tgtccctcct | |
61 | cagtaagtgc aagccaccat accaggccct ttgaacatat tttaaatggc tgatttaaag |
121 | tctttgccta atactaaagt ctaacatttg ggcttcctca gggaacattt tctaatttac |
181 | tgctttctct cctatgtgtg gaccatactt aagtggtttt ttgcatgctt tgtaataaca |
241 | gtctcttgaa aactaaacat tttaaataag gtaatgtgac aactcgnaaa aatcaggatt |
301 | cttcccctac cagggnattt gttgttatta ctgtttactg ttggttactg gtttattgtt |
361 | gttnctntta ggtgactttc ctggaactaa ttatctaana tatta |
|
ACCESSION No. AA453790 | |
ORIGIN |
1 | aacaaatata tttagatata tttaaaagaa ttaaaaaaaa catttcacaa aacatttgtt | |
61 | gccataggaa ttatttttag caataaatgc ccacatcaaa atttaaacat ttttcaaagt |
121 | atgattatct gtactaagta atgcaacaaa ttatgtaaac agagtcagat acatttccct |
181 | gtaggagtca cttccttccc gggattaaag ctgtcccaga catctttcca ggggaccaat |
241 | taagaaactg ctattttcag agcaacagaa ataaaagctt ttatttgttc atttgaatat |
301 | aaaacaggcg ttatcacaga tgtacaaagc gtactggtgg tttaacatac aagaaggttg |
361 | ctgtcctttg cacataaaaa ttttgtttga aactgtggct ggttgagtac atgagtt |
|
ACCESSION No. R22340 | |
ORIGIN |
1 | ttttttaaca taaaggtttt attgaataaa tacatgcact gtcacgtgaa attagttgaa | |
61 | cagaaaggag gttctctact ttttaacccc catcccccac cgctgttctc tatttgcagt |
121 | ggggggtcca gctggaggtg gaataaatgc ggcaaccaca ganaaaacac acagctacac |
181 | acaggcctgc atttggctta tgtgcctgaa aaagaagggc cgacctcttg ataaagaatg |
241 | tctgtaaaag gaattcttac cgtgcagaat atattatcat gggcnantac agttacaagg |
301 | ctgcttctat tttatttatt ttttgagacg gagttcacct ctgttgccca gggtgggagt |
361 | gcagtggtgc gatcttgggc tcactggcaa cctccgcctc ctgggttcaa gcantt |
|
ACCESSION No. AA987675 | |
ORIGIN |
1 | gggtagatag ctagaagtga tagtgctagg tcatatggta aatatatctt caacatttta | |
61 | agatactgcc aaactggttt ccaacgtgac tgcatgtccc atcaacaatg cgtgagtgtt |
121 | ttagtttttc cacgtcatta tttcacttcc cccaggtgtt actgtccttt tttattatag |
181 | cattctagtg ggtaagaagt ggtgtctcac tgtagttttg atttgcatgt ccctgctgac |
241 | tgatgatgct gaccatcttt tcatgtattt tattgtctat tcctacacct ttttgatgaa |
301 | atggttattc aaatattttg cctattttaa aaatggggta attatcattt tgttgcgtag |
361 | ttgtaagtgt atttcatatt ctggatatga gtcctgtatt aaatatatga tttgaatttt |
421 | taaaaaaaaa aaaaaaacct cgt |
|
ACCESSION No. N51543 | |
ORIGIN |
1 | acgattaatg ttttattatt catattttga caaagatagc atattatatt ccaggacatg | |
61 | gtagttacca tgtggggaaa cctatcaaag catttttaat gactgcttag aataactgta |
121 | gaaagtactt tctcaatgat ttttgtatgc aagaaaaaaa atacctgaaa gtaaccaaaa |
181 | gtttcagact ggaaaatatg ccaggaagat tttcttctct cattctcagg tgaggttata |
241 | atccagtttt agcaaatgtt tgacaattta aaatactttt gaaaactgga gatttaaaaa |
301 | atgtaaacaa ttggtaggca cagcaaaatc gtagttttcc cttctgatat tatacatttt |
361 | ggcatctctc tacagttatg attaaccatt aaatnaaggg nagctaaaac gttccaaaaa |
421 | taggttttac caacattcan tttttaaaat tttccattca agctggtaat ccttttgggt |
481 | ttcc |
|
ACCESSION No. N74527 | |
ORIGIN |
1 | aaacgtggca cagtgtgtgt agtgtatgtg actactatca tttgtgtaag agaaagaaaa | |
61 | gtttactatc agagactgta tctggaggga taaacagact ggcaagggtt gcctctggna |
121 | agaaaccggg gaatagagag cgggagtaga aagactgtat tagctgggtg tggcagcaca |
181 | cactgtaggc ccagctactc cagaggctga ggggaagact tgctcaagcc caggagttca |
241 | ggtccagcct gggcaacaca gcaagactaa aaaaaaacaa ctttcttttc caagaatacc |
301 | ctttttgtaa cttttgaatt ccgtattttt taatggtcta tggtctacaa acactcatgt |
361 | gcaaacacat tacacgcaga ataagggatc acctgcacga agctatgaac tatttcctca |
421 | tcccttctag ccccttccta gaggcgaacc ctccgccccc aaccccaggc actatctgtc |
481 | ctgcttgcac cca |
|
ACCESSION No. AA121778 | |
ORIGIN |
1 | tttctgtcaa gctgttcttt atttcangga gagggcaggg gcagagcttt acaggagtag | |
61 | agattttgta tgctattgaa ggtaaattgg tatcagttta aattagattg ttttaagtgt |
121 | aggatgttaa ctataatccc catagcaacc acaaataaaa catctaacaa atatacacaa |
181 | aggggagtgg aaagagaatc agactagttc actacaaaaa aacagaaaag aaggccataa |
241 | agaggaaatg aggggccaaa aaagtatatg acatatagaa gaagtgttaa atggtagaag |
301 | aaagtccttc cttaattact ttaaatgcaa atggattaaa ttttccaatc caaaaggcag |
361 | aaattggcag aatggacaga naaaacaana catnaacatg atagtgatat gcctgtc |
|
ACCESSION No. AA258031 | |
ORIGIN |
1 | ggggccccgt gatctcaacg gtcctgccct cggtctccct cttcccccgc cccgccctgg | |
61 | gccaggtgtt cgaatcccga ctccagaact ggcggcgtcc cagtcccgcg ggcgtggagc |
121 | gctggaggac ccgccctcgg gctcatggcg gccccggtcc gcatgggccg gaagcgcctg |
181 | ctgcctgcct gtcccaaccc gctcttcgtt cgctggctga ccgagtggcg ggacgaggcg |
241 | acccgcagca ggcaccgcac gcgcttcgta tttcagaagg cgctgcgttc cctccgacgg |
301 | tacccactgc cgctgcgcac gggaaggaag ctaagatcct acagcacttc ggagacgggc |
361 | tctgctggat gctggacgag cggctgcagc ggcaccgaac atcgggcggt gaccatgccc |
421 | cggact |
|
ACCESSION No. AA702422 | |
ORIGIN |
1 | aaatgtcttt aattgctgaa tgcctctttg gctaatattt ggaagatcat tatttagtcc | |
61 | tacaacagac gcattgttcc actttcccat cattttgttt gcaaaccgct aaaagtctta |
121 | tttcctcatc tctttgacac attaccaaag tggaccctat gctgtaatca cacaggataa |
181 | tgttggaaag tatgaatatc taaattattt tttaaaggta ttattttttt ccttctgttt |
241 | tcaaatcatt tctgacagtt tctaaagaca tggtcacagc tgcctgaagc atgtcttctt |
301 | cactcatagc atcacctaga tcactcccaa gtgctcctga actggtggct ggcctttcac |
361 | atggatgtga actctgtcct gataggtccc cctgctgctg ctgctgctgc tgctgctgct |
421 | gctgctgctg ctgttgctgc ttttgctgct gtttttcaaa gtaggcttct cgtctcttcc |
481 | gaagctcttc tgaagtaaga tttgtacctg atgtctgtgt catatcttga gaaatgtttc |
541 | g |
|
ACCESSION No. T64924 | |
ORIGIN |
1 | tgagacggan ttgctctgtc gcttaggctg gagagagact ctgtctcaaa aataaaaata | |
61 | aaaataaaat aggagtaatt cacgaggaaa agattacata ggctgctttc ctgcttttct |
121 | tatccacagg cagttctttg caatgactat ttaaaaacta aaacaacatc acaagtcatg |
181 | aagtttgtgc tacccctgaa cttgacaaat tgtctgattc aagtgggcaa agcacaatga |
241 | ttggatgcat ctgaacagaa cctcctctgg aatgggggcc tcactagagt gagctcttca |
301 | tgagccttgc caccaggggc aggggattat tctgttattt tggcctgttg tagccaagtc |
361 | tgcaccccta ggcacccaaa acaaactggg gngagttgg |
|
ACCESSION No. R42984 | |
ORIGIN |
1 | tttttttttt tttttggaaa acactgttta tttgaaaaca atgagacctc aaatatgaaa | |
61 | tatagttaac aatgacattg acactgttgc tagcactttc ccctaaacca cccgtaagtc |
121 | ttggacgcat gtgcatgcag cacacacaca cacacacaaa aaccaaaaac aaagccaaaa |
181 | aaaaaaaant cccaaacaca acattccatg nttgttcatt gaactcctga tgccgggagn |
241 | acaggactgt taaaagattt tgtctcccac attatctctg ggagtggggc acaaagc |
|
ACCESSION No. R59360 | |
ORIGIN |
1 | ttttttttgg ttttattttc tcctgaagct gaaaatgttt cacccatata aatgtggcat | |
61 | tttagactct agctataaac ctcatcgacc agtatgtttt cagagttgtt cacaacaaaa |
121 | tattattcgt ttctaaaatc agttttcact ttttggtgat agtattccag gctggactgc |
181 | ttgaatttta gatgcagaga tcattttata tatatctgtc aatgtaatac agaaaaatta |
241 | catgtgaatt gtttatgtgc cccctctacg tagggacaca gtatcaatca ctcaataagg |
301 | cactgtaaca tcaggtgggt gtttggggat aaataacctc ttcggggttt ctttcaatcc |
361 | cactaccata tggct |
|
ACCESSION No. R63816 | |
ORIGIN |
1 | aagtcannga tntttactta atttctttca ttgtatactt gtatctcatt ttctcttaac | |
61 | actgaaaatc ctgacttcta aagaaatgta actacttgtt ttcttacaac atagtattct |
121 | agatacaata ggttcaaaat aacaccagta ttaccattaa caatgagact actaaatgca |
181 | ttttcacagt gcactaaaat ctcaggaatt cactggcaat ataattcatc catgtaataa |
241 | aaaaccactt ggtaactcca aaactattca aataaaangg taataacaaa tttaaaaatg |
301 | gcattttgng ggtttcttcg gaattttttc accctttata ttcccccaaa gggccttctc |
361 | ctattaattg nggaggggcc ttgggnattg g |
|
ACCESSION No. T49061 | |
ORIGIN |
1 | ggaccaaaga actttatatt tattttaaat atcaaagtaa cacaaagaac tagttcaata | |
61 | tacagtacac ttcctactct tcacagagaa ctgaaatttt ctataaagac atttatactt |
121 | aggaaacatc agacaaccaa agtatgtata aaactcacaa gatattttac acacagttca |
181 | caataattaa ttctgatatt ttaggntttt tctgtcattg cttttaaagc atccttaatt |
241 | taaaaacaaa aattattatt tgaggactgg aaaacaggtg gcaaaggcat ttctactttt |
301 | aattatacac tggtaaatcc ccccttaatc caaaacattt tacttncaca t |
|
ACCESSION No. AA016210 | |
ORIGIN |
1 | cacagcaatt catctttgct tttattaata atttcaacgt atgttttgag cactttacaa | |
61 | tgtaggaaat gctttcatag acattatttc ctatgattct cacaaaacct tcactgaaaa |
121 | aaaagacttc aaggtcactt gccctatgtt tataaaataa tccgctttaa ataagcagat |
181 | aggagtccaa aaattcttac aatcataaga aaaaaaaagt ctaaccagta cttaattatt |
241 | tcttgtcatg attactttgt tttaacgcca ctgtttcctt gcttccccca ttttcttcag |
301 | ataagtttac tccttttggc ttgtcctgca tccttttctg acagctgccc tgtgtacacc |
361 | tgccttaaac atctatcctt ctactctgga atagactaag ccaaaagcaa ttaagaaata |
421 | tttcattcta aagaaaacag aattttagtc caaaacccaa at |
|
ACCESSION No. AA682585 | |
ORIGIN |
1 | cctgtgggct atattttcct gtatgttttg tatttttttg ttggaaactg aacattccaa | |
61 | gttttacact ggggaagctc tggaaactga attattttac tcctccagga ttgtttattt |
121 | ttaaaatttt gctggcttat gataaagggt atttcgagga aacagataaa gggatgtata |
181 | gggcgaggta tgggggaagg ggtgcagagc ttccatgccc tccgtaggtg caccactctc |
241 | caggaacctg caggtgttca gctatgtgga ggctccctga atgcggtcct cttgggtttt |
301 | tatggaagct tcataatgtc agcattcctt cccccaaggt atagggcaag actctctctg |
361 | gggaaggtct taggaccaca atcagaaaag tgggcagaca ttagagtcct gccttggggc |
421 | agatgaaagg agggcaggag aaggtcagag aaattgtttt tcttgag |
|
ACCESSION No. AA705040 | |
ORIGIN |
1 | gtagagtcgc ggtctcactg tgttgcccag actcgtctca aaaaactcct gggctcaagc | |
61 | aatcctcctg cctcagcctc ccaaagtgct gggagtctag gggtgagcca tcatgcccag |
121 | ccaagcctga ttttaaatca ggtctctgcc actagcagct gagagctcct cactgataaa |
181 | tcctttgcag ctggaagtat tcaatggtat ccagtatatt cccaatggct cattcctctt |
241 | ggacagagaa actcaagtta aatgaactct tttggctgtt tttctccctc ccctttgttt |
301 | cctccctctc ccttgcctgt gtctctctgt ccactctctc aggcccttc |
|
ACCESSION No. AA909959 | |
ORIGIN |
1 | ttttaatggg caaaagaaca agttgcagtc aatggctgca gaggggtgtc tggggtccaa | |
61 | tgtgggctgc actttgtggg tactgaggaa atgggaagat gctgcttcta ggtcagctgg |
121 | tgggttggag gttgggggct gtaattagca gcagccttag aactgggatg cctttcaatc |
181 | cctcctggcc ccttatctct gtggggcagt cacaggacat catctgtttt attcaaagtt |
241 | gggacttgca gcaggagacc ctgtcctgca tggagtaggg gtcctctgtt gacaaacttc |
301 | ttggtttcca gctcttcccc atctgcagca ggcctctgga ta |
|
ACCESSION No. AI240881 | |
ORIGIN |
1 | tcggttaaga tttttattat tccagagaaa aattagaatg tatcggtaaa agaaatagga | |
61 | atgcatattt caactcactg tcacaaacag gtgttttatt atcccaaatg acagtgttgc |
121 | ctgagatgat gcatgtggca gacgaggaac caatgagtcg gtatccttta ggacaagaat |
181 | atttaatttg ggatccgaac tggatgtctt tgatcacatg tgccatgcca ttcacaggat |
241 | ctggaggatt acgacatgat ttacgtttgc acttgtcctt agcacttgtc cagactgagt |
301 | tttttaggca gatgatagaa aacggtcttc cggaataacc agggcggcat tcatagttca |
361 | gatatgtccc aatgggaaac tcagagtcat cagttaggtt ggtaggcctg gcaaatggaa |
421 | gcccattccg gacattgcat tga |
|
ACCESSION No. AA133215 | |
ORIGIN |
1 | caagaacatc ccttttaatc acaaaccact catccacaaa tgtggctatg gggtaagcag | |
61 | tctaggctgg gaccctttcc agaggtaagt caaggtcacg tccctgcccc cttcctaggg |
121 | tggcggtggc tccagccagg ggggcttcca ggttaatacc agagcctcgg ctactctgga |
181 | ctcctgtgag ctcttcttgg ctggaagaag gggggcattg tgggcctgct ctgtcccaag |
241 | gctccagaag ctgcccctac ccaggcctgc ctgc |
|
ACCESSION No. AA699408 | |
ORIGIN |
1 | taacagtctt aatattcatg tatttattct cagaacatac aaacttatct tctcagagaa | |
61 | tagaaaacag agatttcact cagtgacaaa gatggacaca gccagttcac cgtgtccccc |
121 | catctactta gaaaatcccc tgggggaggg gatgcctaga gcatacagca ccccttggtg |
181 | gccggctgtg cacaggtcta aagactctca acttccttta ccatccaaaa aggaaaacag |
241 | ctgtccagat gacagtaaga ttccactgtc tgtaatcctc atggtgccag gtctcctggg |
301 | gcatctaggg caatgatgct actgcagttt atgcagttac acagtcaagt ctgtgccaaa |
361 | ggaggtccca tccggcggcc aggtttctgt |
|
ACCESSION No. AA910771 | |
ORIGIN |
1 | ttttgttgta gaaatatatt tattaacata agcagttcac aatttactgt aagaaaaaaa | |
61 | gcaagctaca aaacagtgat tccatgttta tattaaaata aacatacaca aattaaaaat |
121 | ttccttagat atccatttaa tctctgggat cataagcaat gtttaggtat tttttgctca |
181 | tttattgcct aggttttaca caatgagcat atatgttaat tgtgtaattt aaaattatgg |
241 | aattaagtgc aagagttcct aaccaccttt tacaaaactg ttatgagaaa atacattcta |
301 | gattcaaaca aaaactaagc aatatatccc ttattctaac agctctaaaa tctgttcttc |
361 | tcattatact cccac |
|
ACCESSION No. AI362799 | |
ORIGIN |
1 | tttttttttt tttttttgca agggctgcgc ggcattttat tttctgaacc ccccacagca | |
61 | ggggcggcca gtcctgctgc aggcagagtt tcagtcttcg gagtttgacc ttctggccca |
121 | aggtcatcac agccacaggc ggaggctctg gggaaaggtc cagttcctgg gatgctggcc |
181 | cctaatgatg ggcccatctt tccagtgccg cccttccctc ccgcctggca caggagttct |
241 | ggagccacgg tcctgagtct acagaacagc ccggtcagcc tcgtcccgcg gtgcaagcga |
301 | ggcctggcct ccctccctgc ctgtccttgg cccggccaca tcactccctg cgtttcttct |
361 | tcttctccgg ctcctggaca ttggccgcct ttgctcgggc actggtcagg ggccgaggtg |
421 | tcctccttct ttggcgagcc cctttttggc cacgggccct |
|
ACCESSION No. H51549 | |
ORIGIN |
1 | atacaacatc tttatttggc attgganatc ctgacatttg tncattacag ttccttaaaa | |
61 | aacaaaccaa aaaatcagaa caaattaatc aaaaataaag atccaatggc tctatttaca |
121 | tatngcaaag acagcccagg natcttccnt gcacacacac accccgcccc gatacagtta |
181 | aggggttaat aagctttggg gagcgcagga ggcaggttcc acagttcatc aatcccaagn |
241 | cacccccatg aggtaggggt gcctcacaca gccagacggn tatcaagagt atgattggta |
301 | gctttttcct c |
|
ACCESSION No. R06568 | |
ORIGIN |
1 | ctgtcctgat tagaattaat tttcataaag agaacaagaa tcttgactgg ttcacccttc | |
61 | aattccttgt gcccgcaaca gtgaccggca catggaaagc attcagggaa taaaagcaca |
121 | atggaaaatt aaaacatact cactgcatgc ctgccaccta taggaaccaa attaaatcac |
181 | tgccaatatg gcatgggggg aaaaccttcc catttttctg ggaataatgt ttacaaaggg |
241 | tgggaaaata aggtggcaca ttcacctggg gtggggcatt ttaatttaaa cgctngttga |
301 | ccccagtngg ttgttacntt tttcaggtgg aatta |
|
ACCESSION No. AA001604 | |
ORIGIN |
1 | cttatgaata atgttagaaa tggaacatga tgttttaaat gtatacataa accttccaat | |
61 | taattatcag gtgatccagt agtagacctg tgacctctga aggctcctgc ttctcatccc |
121 | ttcccttctg ctgtgatttg ttgtcttccc tctgctcatt ccccttgtgt ctgtttcttc |
181 | catcctctcc ccatgctccc tctgttgtca tttcccctta ctctccactg cacccagcct |
241 | ctgttcataa tttttactgc aattccgatg attgaattat aaactggaag ggagcaggga |
301 | tattgatctt catgtagttg gacatgtact agactcacgg agaacaagga ctgggttgta |
361 | ggcacaatgc tgtgtgggtt ttgggtaaat ctaactcaca ctcaacttga ttttgttttc |
421 | c |
|
ACCESSION No. AA132065 | |
ORIGIN |
1 | gagacacagt acaacagtct ttaatgtata tataaatatg cctacataac agagtttgat | |
61 | aagagaagtt ttggctatat acaactctgc atgtaatcaa actctagaac atcaaatgca |
121 | actccactgc atagctgttt tgacagagca acagttaagc ataaaatagc tttgcacctt |
181 | attattttgg agcaaaataa aaaataacca ccacaaaaaa aatctctaca ataatttaaa |
241 | ctaaaaatgt tgttgaggat agggtaaaca acaaaaaaga aaataatttg atccatatgt |
301 | gatatttggc tgaagattaa cagtgttaag tctaaccaac agcgagataa ttttaatttt |
361 | cccaagcatc ttnctaccgg tttattagcc atatttggat attaagggga agggcatttn |
421 | gccctttacc aaaaccn |
|
ACCESSION No. AA490493 | |
ORIGIN |
1 | tctttattga cttattgtaa ttttttggca tacaaattac ttaagtatat ttacaattct | |
61 | tacataatgt acattttaga agataatgta ctttgctcca tttacaatga caaactactg |
121 | taaaactaca ttcatgaatt agatacaaat cctctacata ctaataaaaa gtaaatggac |
181 | tgttggttat acattcttta aaatatacct tttcacaggt agcaagaaat agtacatgta |
241 | ataagtcttt atgactggaa tga |
|
ACCESSION No. AA633845 | |
ORIGIN |
1 | gtttttaaaa gtcagggttt tttgttgttg cttgtgtgtt ttataattaa catagtttat | |
61 | ttttaatact ggcatccaag aatcctggtt tactcaggtg cagaaagact ctctaactaa |
121 | gcagccaaaa aaatttttgg tatgcaagtt ttatcatttt ttaatttgca tatgacttga |
181 | acgtgtcttc aagtataggt ctacataata actttttaag aaaattataa agctcaatac |
241 | aataaatcta atacataaat gctgcttgta agtcaaatat ttaagagact ataaaaatgg |
301 | gtaattttgt gataaaattt agaatcattt gacaagagat caatgaattg |
|
ACCESSION No. A1261561 | |
ORIGIN |
1 | cactgttaaa aatacattta tcattaaaat atattacaca tggagacagg atgcatcata | |
61 | tacagtttgg aagacttgct ggcccagaaa atcccacttg tttcaccgaa cactcatttt |
121 | ttcagggatt ttacatttta tttttagaga cggggtctcc ctctctcacc cgggctggcg |
181 | tacagtgatg tggtcatagg tcactgcagc ctcaaactcc tgtgctcaag tgagccaccc |
241 | acgtcagcct cccaagtaac tgggaccaca ggcacgcatc accacgccca gccaattttt |
301 | taaaaatgtt tttgtagaga gggggtctcc ccgtgt |
|
ACCESSION No. H81024 | |
ORIGIN |
1 | agcttcagcc tttattaaac aaaggaggag gtagaaaaca gataagggaa cagttaggga | |
61 | tcccttcttt cccctataca tacacagaca tacaaacaca cgcacccgag tgaatgacag |
121 | ggaccatcag gcgacagatt gaagggcaga gggaggcagc accctccgag agttggcccg |
181 | gacccaaggg tgggctgaga cctgggccag gggcagccgt tccgaggggt tntgcctgag |
241 | cagtttggag atgaggtcct gggctcccgt ggggcacaga agcggggaac tttaggtcca |
301 | ccttggacga tggcgg |
|
ACCESSION No. N75004 | |
ORIGIN |
1 | tcaagtcata agataaagtt taatcatttg atcatgttaa aagacacaaa acacagccaa | |
61 | tctaaccaaa tttcaggcat gcatttacat aaatatatta aattaagaaa agaaattgta |
121 | cacttaaacg tccttttcac ctagaaatca ttaaatccac agatcaacaa taaaaccaat |
181 | tctctgcatt taccacttca agatacaatt gttctatttt aaagataaca caaactncac |
241 | tagtctggtt aggaatttat ntgcattata catatattat |
|
ACCESSION No. W96216 | |
ORIGIN |
1 | tctcaggagg tagaagcttt attatgacat cttcaaaaga caatcaaatc aatagacatt | |
61 | tgctgagcac ctgctgtgtg caagcccgtg tagacagtag ggtccagtgt cccacgcatg |
121 | gctctcgaat ccccggggag aaaaatcaca tcnggggtca gggagttttg cgtggctgag |
181 | aacaaagtgg gtttctgaac atcaaagtgc aattcgcttt acggggcaaa ctccgangcc |
241 | cagccccgcg tngggaagcc gcagcngggc gggcccgctt cctggggctn gcggccgggg |
301 | tttctctaag ccgcacgcnt tgcgtggtgt tgcggggcct ctcaagcaag cccggaagca |
361 | gcatccttga gctccggttg ttggagcgct gggacctctg gctgccgccc ccgcagcagc |
421 | agcaaccact actccgctgt c |
|
ACCESSION No. AA045793 | |
ORIGIN |
1 | caaggtatag ctaattttat tattatcaaa caaaactagt agatataact tccaggaaat | |
61 | aagttacata aatataacag aataaattca ttttcttaag tttcaaatta aagatgatta |
121 | agaaatacag ctttatgtaa agtttctgct ttttctcaac cacgcctaaa gaggaaagaa |
181 | ctggcagcag gaacacttgc tcctaggaaa caaatacaac aaaattataa ttaaaaagat |
241 | cttcaagcta tcaaaatttg tgagagaagg atggtaagaa tgcagtagaa attaccanat |
301 | gacaaacaaa atcctatcag ttttcaggtt ggtcaaaaag taacttccat gaatatagcc |
361 | tgtggatccg gccat |
|
ACCESSION No. AA284172 | |
ORIGIN |
1 | gtgttaaagt tggatggatt tattttttta aaggcccagt acaaaaaaat ggttgaggaa | |
61 | agtgactctt caacaaaata tacacctgta gaaaaaaatc cctaatatac tgatatttaa |
121 | ttgaacggaa agtactaaag agaacatact ttaatatcta ggcacaattg gtcaggtact |
181 | aattataatt tctgttctca tttaaaagtt taaaccaatt cttcaactgg actgatgtgt |
241 | gtgagtctaa tacagagaag gcacctctct catctctcac tctccttaag gaccttttga |
301 | gagaaactct ttgtaacact ttaagggaca cagacaatgc actatatcta agtatagata |
361 | tagttattta acatac |
|
ACCESSION No. AA411324 | |
ORIGIN |
1 | tttttttttt tcccaaacaa tacatatcag attttatcca ttttgttttc tacatgttct | |
61 | ttgtgactca agtttgacat tagcatttgc accccaaatg agttccccta caaataaaat |
121 | ttgttcatgt tgacacaaag aacacaaagc aagtatagat ccctcaggaa gttgtcacaa |
181 | ctcttgataa gattaactcc accactatca tcactttttg ctttgtcccc tagtttgaag |
241 | cctgctggct tttataattc aatgagaatg actccacact cttctccaaa gcgcccatta |
301 | tttttagttt ttcggtgcgc gactcaacat aaagacctgt ggctcttatg agctgcctgt |
361 | ttttaaatgg tgcagtagtt tcagtttcca tttaataagt tcccagataa caaatggaga |
421 | atgggaagaa tcttctcaag gtcacagtga aggtaaaaat aaattatctc catcactgag |
481 | aggct |
|
ACCESSION No. AA448261 | |
ORIGIN |
1 | tttccagaaa aggatatttt ttttattcaa gtaactgcaa ataggaaacc agagagggag | |
61 | ccccaggctg ggacaaatca tggctacccc tccccaacag aacaggggga ggaggtggcc |
121 | cctacaccct ttatggtcga ttcgggcccc cttgctcact ctgctgcagc atcctagggg |
181 | cagggccagc cttccctggg actggggtag tcggtcaccc agcctgccat gccccagccc |
241 | ctcttcccca caaagagtat cttgggggag gggatcgtgg gcagaacagg aggcaatgag |
301 | gatgaacatt tggcgctggt agcagcagca atgacggatt gtcgaagaat ggaacattga |
361 | aca |
|
ACCESSION No. AA479952 | |
ORIGIN |
1 | aacagtctgg ctgttgtttg aattaaactc ttaaacagga tgtttagtta gagggtaatt | |
61 | gttgagtaat gatgcataca acagcatact tccctttctt gctgggggtg cagcttttca |
121 | gttttcttgt tttactttga cagtgcaagg ggaactgaaa ataatttcca ttgtattatt |
181 | tatcttagtt cagctgaggg ctttatgaga cagtggatgg ggaggcagta agacggtgat |
241 | gagataaaat gtgtgtgttg cactgactgt ctataaagtt atcctttctt catgaaaaag |
301 | tagcatttaa atctggatga gtttataaag gattacaaaa tgctgattta tagagtaaac |
361 | tttaaaatat taaagactaa agactaaaag aagagtaata atgaagtaat gtag |
|
ACCESSION No. AA485752 | |
ORIGIN |
1 | ttcggcagca actcctttcc tttatttctt ccccttgtaa agggaaattc aagttcagca | |
61 | gcattccttt cctgccccaa gtcctcaacc agacaagagg ctgcaggcac caaatcttgg |
121 | gctggataat ggcaaaggcc tcagaagctc acctccagct ctgagcttca acagctgttt |
181 | gtaccagtga gtcagcatta aatccaccag aaaagaacag caccacccaa agactggggg |
241 | gcagctgggc ctgaagctgt agggtaaatc agaggcaggc ttctgagtga tgagagtcct |
301 | gagaca |
|
ACCESSION No. AA504266 | |
ORIGIN |
1 | tttttttttt tttatatata tatataattt tatttaaaat ttagatccct attcccacac | |
61 | tctaataagc tgtataattt ttgtttagaa tttttctgca aacatactac aataagcttc |
121 | ttttatttgg agacaaaata cagtggcatt actggaagga atatcacaac attacatttt |
181 | tatcttaaag gacaagcaaa ctttcagggt tgataatggg ataagcatgt ttgagactgg |
241 | ttaccttctg gcagttcact gcatctggat atttctgaaa agtatagaga agctcttgga |
301 | ttttaaaaat atcttaaaat acttttagat gaaaaaattg taaaagttct gcttataagt |
361 | ttacttttct ccacaattac aatatttaaa acaaagtttt gttgattgac gttttaagca |
421 | tttaaattta gaatgctaaa aacaattcta tcctacactt tcttcagggt aggggaataa |
481 | atacatcctt aacattgttt tctggatgta aacagaaatc cagcagaggt catcattatt |
541 | tagtacaacc agtaaataaa tgtaagagaa t |
|
ACCESSION No. AA630376 | |
ORIGIN |
1 | agcttggcaa acctttttta ttttgtgata aaaatgcttt catataaatt tcatcttaac | |
61 | tacctttaga atgaaacgga aaagtaaaaa caaagtgtgc attttcctta ctacgtttag |
121 | tcaggaatat gcggtcattt tattggttac tgggtttctc atacaaacag atataatatc |
181 | acttttaaga gaaatgtaca caaggaagta accatagtac cacttattag tgggggcctc |
241 | tgggtacata aatgtgtcct cccaaatagt catcatacat tcaatggtat t |
|
ACCESSION No. AA634261 | |
ORIGIN |
1 | atagtgaaaa tatactttat tttttaatac aatagctgcc agcaatatac tggtgctgat | |
61 | gttccaaaga taaaagaaaa tacatgcatt ctataataag ctttcatttg cctgttcaag |
121 | aaattataaa gaaaatactc caattctgtt caacattacg gcttgaggag ttgaaatttt |
181 | tccatgataa aaatatactt tgtgtggccc aaaccttgac tatttataaa ggatggagtt |
241 | tttaaaagcc cacatgtatc aataatggat gctcccctct ctttgaatta aatgcctaaa |
301 | ttcaaattaa tgcaagaaat tggtgaatca ttaaatgatg aaatttgtat caaaatgttc |
361 | atgaaaaaat acatttctat ttcctctaca tttttacttt gtagttattt tctaaatggg |
421 | tttaagggca cagaaataaa tgctatctac atgcaactct ggagagattc aaaacacaac |
481 | agaagttaac atgcctaaat cctagagttg atccatttag tgtaagaata aatgtcagaa |
541 | atc |
|
ACCESSION No. AA701167 | |
ORIGIN |
1 | ggtagaggca aagtttcgct atgttgccca ggctggtgtc gaattccagg cctcaggtga | |
61 | tcttcccacc ttggcctccc aaagtgctgg gattacaggc gtgaaccacc gtgccaaacc |
121 | tacattttta gatttattat ggtgttctga ttaacaataa agctaggtta ttagctgcct |
181 | gggaagagga ggaagtagat ttttacagtc acttttatag aaactgttaa attcacatga |
241 | gaaattccac cttacgagaa ttggctccct gacatgtctt tggactacct ctgtttctct |
301 | aagtttttgt ttttttctgg tgtctgaatt aagttggtga cagatttggg ggatatttga |
361 | gtagcacttt atctagagtt gc |
|
ACCESSION No. AA703019 | |
ORIGIN |
1 | ggcatttcag taaatttttt taatgacttt aatgattctt atttaagaaa aagcccttaa | |
61 | ataaatgcta ccaaggcagt aatatttgac catatgaacc agaccaaata ccctttaatt |
121 | ttagtatatt aacctctgct gtaaatgctc ttttaacatt gccacatgta caaatttgtc |
181 | tagaacttca cgacacaaaa gtgtgcaaat atgagtctaa gattgtgctg aaatagggaa |
241 | aggctaacac tgatgtgcaa agtaaaaaag aaagataacc gcttctgcaa caggtaataa |
301 | aacaaggaaa aaacgagtta ggtcctgcat gtgtctccac ttcattgctt ccatgtttga |
361 | aaaagggagt ctgttctttt gctaggccat gaggctggaa tccacttggc atactgtgtt |
421 | gagaggtcta agttcagtgg tgctctcagc agcagccggg agg |
|
ACCESSION No. AA706041 | |
ORIGIN |
1 | cgctgagctg cttatttatt gaaaataaac gacggaaaag tctggccttg ctcctgtgca | |
61 | agcttggagg cctgggtcgc cgctgtggac aagcgtctta gtgtcatgca gaccagaagg |
121 | cagctgctgt cccagggccg gggccacctc actgcctctg atggggactc ccagccccca |
181 | tggctccgct gtgccctggg caggggacgg gctgggggca ggggagggct ggagcccagg |
241 | aggcagcaca gcagccagaa agccgcacgc tgagcctgca cctatggttc cgggaggggc |
301 | ttgggccgtc acccaagtgt gatccctaag aacaggaggc ccagcaccct ggaaggaggc |
361 | gctggaaggc ggggcggtgg tggccccgtc a |
|
ACCESSION No. AA773139 | |
ORIGIN |
1 | ccatgaacac agtagtgaga tattcctttt ccactcctac actatcttct gcttaaaacc | |
61 | ctctgagggg tcccatctct ctcagggtga tgtctagact tcttctgagg ctagaccagg |
121 | tggtgcggcc ccatgtgcca cgcacccaag ccccctgcct cagtgtcccc catatcccac |
181 | accacagggg ggtggctgcg ttctgtatgg taggtggtgc tgaccactgg gcctctgcac |
241 | acgctgctct cagttccctg gccaactctc cttcaggcct cagc |
|
ACCESSION No. AA776813 | |
ORIGIN |
1 | ttttgtagag ctgggatctc actatgttgc ccaaggtggt ctcaaactcc tggcctcaac | |
61 | tgattctcag gcctcagctc cggaagtgct ggaatcacag gcaggagcac ggtaacccgg |
121 | gccccacagg ggtttggggt c |
|
ACCESSION No. AA862465 | |
ORIGIN |
1 | tttatgctag gcaaggaggg atgattattt attagcttct acagattaga caatggggtg | |
61 | ggggtgggct caaggtgaga tgattttttg ggtccaagtc tactcaagac aggcatccca |
121 | gtcttcggtc tccaaatcca cctcctgtct gtccccccac actgctcctc aggccttgtg |
181 | gatccattga ctgtgatttc tgtggttcag ctcccacatc aggcaggaag ggcagctact |
241 | gggtctgaga tcccacattg cctccaaccc ttgcttccta gctggcctcc cagggcacca |
301 | cgaggggctg ggccaggctg ctgtgctgca cgtggcagga gtagggggct gtgtcctgcg |
361 | ggggcactgc accaccaccc aggactggta agtgccattt ccattgtgaa gaacatctcc |
421 | cgtactcagg ctcctgcacc tcgcggcccg agtccagtgc acatcaattt ccctgggtag |
481 | aagtcgtagg ccagcacttc agtttcttct tttctcctgg gggctggtgg ctggtgacac |
541 | cacagaggga ggatctgccg gtccaggata tttttgct |
|
ACCESSION No. AA977711 | |
ORIGIN |
1 | tttggcattg taattatgca gaagaaaatc tttattctta gggatcatgc tgggaactga | |
61 | gggatgaagt atatgcatat tccaaatggt tcaggaaaaa tcctgtctat aaagcataca |
121 | tgataaaatg tcaacaataa gacaaactag aggaaggata tacaggtgct tactgtcaaa |
181 | tttcaaattt tctgtaggtt tgagagattc aagatgaaaa cttgggggaa aattatatat |
241 | tctgataata aaacagatgg gaaacaaaga gggcccataa gacagtcact gattaagatg |
301 | ctttctacat ggatgggcct catccttttg tccaaaggga ctacctggca tctgttccat |
361 | gttagtgaca gtgactcacc ccaggttgct gcacagatat gagaggcttt agatcatagc |
421 | acagtc |
|
ACCESSION No. AI288845 | |
ORIGIN |
1 | tttttagatg ttttaaaata catttatttc atgtcgtttg tccccagggt ttggagtttg | |
61 | atgttctgga ccaagcgtag gctctgagca aatgctacca gggctggaga atcagttctg |
121 | ccacttccta gttaagtgat cttagacaaa tttccgcgcc ttagttttct tctcagagaa |
181 | atgagactag tcctatccac actatggaca agtggtagga ggcgaaggag ctcacgtttg |
241 | taaagagcct tgcacggtgc ctgagacaaa ttcagtgctt agcaaatgtt agctcacctc |
301 | tcccttttct tcctgtatcc gattttgtat acaaatgtgt agaaaattta catgaaataa |
361 | tgcagaaag |
|
ACCESSION No. H15267 | |
ORIGIN |
1 | tttttttttt ttacatgaag tagaactttt atttggaaag ttgaatttca tgtataatga | |
61 | aaatattttc aaaccataca tagtcataag cataatacaa acaccaccta caatacaaac |
121 | acgttttata aagttctact atgaatatta atccaagcca aaagaaaaag gtaatcacgt |
181 | gaacctgttc tacatacctt tcatctcttt tgatgacgta atcgaacaat ttaaggtaca |
241 | aaacaangaa agctttgggc tgaaccctac ttatttcact ataggaacac taggatatat |
301 | actaccacag gtaaccaaac ccaatcccat tataattaat ttaacattgt tacatggatc |
361 | ctatcttaat ggnatgtaaa cat |
|
ACCESSION No. H18956 | |
ORIGIN |
1 | tttttttttt ttttttttac atgtaagaag tggttttatt ccaggngtgt gtttcataaa | |
61 | gacgaggtcc tcaaggacag ctagtggcac atgctttggt caagaagagg aaaagcaaaa |
121 | acagaacagg gctgcgttgc cacaaaggac cggctgataa gtgcagagcc tgatctgacc |
181 | acagcaaagg acagagagac cctcttgaag gccctctggt cagcagtcct cttacattca |
241 | acaggcgcac ccggctcccc agccccaaag gtccatgccc gagtntggcc cgggcttcta |
301 | gtccatcctc tgggggagag gcctttgccc tggggcccag ttttgtccta aggtttnggc |
361 | aggganggtt tcccagatgg aacaggggga tttttagggn tgcacttggg tttncggaag |
421 | gaaacntcac gacagaggga caggcaaagc ttggccntgg g |
|
ACCESSION No. H73608 | |
ORIGIN |
1 | aaattttatt aattttattc aggaaagaca ttgactgtta agtttttttt tngggggggg | |
61 | ggtgatgtct tgctattttt taaaaattat atccagacta tgaatttaat atttactacg |
121 | gctaatcaac tgctcatgtc agtaatcaaa gncagaaatg agccttatac gtacatctac |
181 | attaaacaca cacacacccc tttaaggggt gctcagtgta gnttctaatg tcagtctgtc |
241 | cattcaaccc agggcccaag gttgcatcac atcaccaagt tggaatcatg aagacagccc |
301 | agatttgact gacatgggca cagcagggct ccctcaccac agcccntggc accagttaac |
361 | tatttctngc tcgngccgaa ttnttgggcc tcgagggcaa ntttccctat tagtnag |
|
ACCESSION No. H99544 | |
ORIGIN |
1 | gcgnccgccg cccccgcctg ggccgcgctc cccctctccc gctccctccc tccctgctcc | |
61 | aactcctcct ccttctccat gcctctgttc ctcctgctct tacttgtcct gctcctgctg |
121 | ctcgaggacg ctggagccca gcaaggtgat ggatgtggac acactgtact aggccctgag |
181 | agtggaaccc ttacatccat aaactaccca cagacctatc ccaacagcac tgtttgtgaa |
241 | tgggagatcc gtgtaaagat tggganagag gagttcgcat caaatttggt gactttgaca |
301 | tttgaagatt ctgattcttg tcactntaat tacttgnaga atttataatg ggaattggga |
361 | gtcagcggaa cttgaaaata aggcaaaata cttggtaggt ctgggggtnt ggcaaaat |
|
ACCESSION No. N45282 | |
ORIGIN |
1 | ctaggcataa cataaattgt tataattgat cagaatatct tgaatatatt tttacagata | |
61 | actagtggtt tctactagca gattaaaacc aagagaaaat taaaagtaag ttcacattta |
121 | aaaaaaatta taagcaataa atacagcact acagccacca ctaattctat atacattgga |
181 | ttacatttaa acaaacactg cattccagaa tgaatatttt atgaataaat gcattggaaa |
241 | ttaactttag gaaataaaat gacaaattac gaatttagaa aattaaaata tgactttcac |
301 | aangtaatca cagtaaaatg cagatctaca ttttaaaagc tagaaatttc cccaaattta |
361 | tttttttgga cagccaagaa gnttgcctta aaaa |
|
ACCESSION No. N48270 | |
ORIGIN |
1 | tttgcacctt gaaacaattt aataatgtat tacattatag tagcatcaca gcagcagtca | |
61 | ataatgccac tttagacaaa aatcagtatt tccattatgc attctgtgta taagaattca |
121 | taaatcggta aaagtcattc taagaaaact tggcaaatac agctttggac tggaattggc |
181 | atttctttgt ctacttttcc ttcccctaga ttctttgttt taaactacag tattcatatt |
241 | ttaaaatgtt ttaaattatt ttaagacgtt aatatagcag ttacattttt gaatagttat |
301 | ttgaaagtga ctgtaagata aagttttaga gaatctatta atgggatagg gttgatttac |
361 | attttcacat ttttcctaaa aatcagcttt ggttttagaa ctgattggtt tttcattttg |
421 | ggaa |
|
ACCESSION No. N59451 | |
ORIGIN |
1 | aaaatcactt caagaagcat ttattgagaa tctaagacaa acaccctata ttcaaagagc | |
61 | ttacagttta tggaaaggcc agccaatcaa tatgcaatat ttaagtcttt tcattgaggc |
121 | aagtgttgat tttgagagca gagagatgat gatcgttttc gagctgagtt accaaggttg |
181 | gagcttacta aactcacaag ggcagtttca ggaaaggaaa ataccatctg caaaggtata |
241 | tggctcattc aggggctctc tgaattgtgg ctggagcaaa aggtttgaaa tcttttttct |
301 | tcccaagaag atgaaagagc tcctggagga cagaaactgc tttttattcc ctttgtatct |
361 | ctcacagcac ctggatactt aagactaaac tattctttca ctcatatggc ccattatcaa |
421 | tgtcagcatt gtaaggccct gatggg |
|
ACCESSION No. N95226 | |
ORIGIN |
1 | tccctttctc cctgtttccc tcccttcttt ccttccttcc ttccttcctt ccttcttaga | |
61 | attcactgaa gtatttccta ggtagccttt tacttactac tttaatcaaa gcttatcttt |
121 | gtgcccaatg tgtaaaaagt gaaaatgtct cttcgaaatt ctatattaca atatagacag |
181 | agaagttggg ccttgagggc ttgagtttca cttaaatact atacacatgt ggtatcacac |
241 | aaggtggagg gggagggaac aaacagaaac ataacaatta tttttattct gtctttacaa |
301 | aagaaagcct cttctctatg aaaaagtctt tttggcatct gctcccggaa acctgccccg |
361 | agaacacgtt ccccattgct ttgcaagcat ctctttttaa aagcacanca ctgtccccgg |
421 | gagtcacgta ggttggatta anctgtctta gttgaccaac gaagaancac tggatgagtt |
481 | ttccagggat gantggttgt ctggggtgga acatatagtc ctgtctacaa caaatgtaac |
541 | tcctgatatg ggacnatgaa cncagtgtgt gacccaggag tgnttgatct gtnaacantc |
601 | gcatgnaatt |
|
ACCESSION No. R37028 | |
ORIGIN |
1 | ttttttttct ctaagtgata atgatatccc agctagaata attgtgctct ccagaagcaa | |
61 | ttaatctgat ttgcaagcac tgattttttc ttttgcaaaa actaataata ttagcctgac |
121 | caattatgaa ataattccta aatttacaaa ttcccaaatt tgtgctttca tggcttcctt |
181 | ctattttaaa tctatattat tttaaacaaa ttttccttaa gnaaaaatga cttaacttca |
241 | taaaaatcta cccatttatg gtaaataaaa cattaaccaa aaaccaaaat taaagggntt |
301 | actataaatg gnaacattta cattgctggn tattaaatcc ctttccttgg catt |
|
ACCESSION No. R66605 | |
ORIGIN |
1 | ttttttatcc ttcttaannn ttattacatg ttttattatc ctgtccccag aggtgggttt | |
61 | atccagaaac caagaaaaaa aatcaatcag aataaactca aaaaaaaaag gtagggggag |
121 | caaaaccatc aaccaccagg gcagccaggc catcagccca cctccacctc tggagggtcc |
181 | ccagagaccc acgcccgacg cagacccgga ggaggcatca gcaagggggc ccgggcagag |
241 | aatcggctat gtctttcatt atgaggaggc agggagagac gggcagagat atgtttgcta |
301 | gggtgantat atattttata ttaattaaat ccgtaagttt aattaaagta aataggtatt |
361 | tctctggaag tttttttaat ttctttcntt ttttatagtt tttttggttt tttgtggntt |
421 | tttttttttt ttttggggtt t |
|
ACCESSION No. T51004 | |
ORIGIN |
1 | gcagctgttg tcttccaact cagcggcagg tttgctttcc ccacggacac tctggacctt | |
61 | gtagctcctc aagcttccct gtctattgag cagataggaa gccgtgtcaa atatgtggca |
121 | ccttgaggaa atgcctagtg aatgacagta tgtcctattg tgctctaact ttatttcagc |
181 | cttatttctt ttctgaatat tatttttcat ttatcttcat ttccttacct attttctttt |
241 | cttctaaagt atgtatcttt gttagctcca tcatcctttt tgggaatgag gcaagtataa |
301 | aaataaggta aataaataag gaccccatcc ctaggtattt ttaaggaaac cacccttttg |
361 | cggggcacac ttggctacct tggggtcttt agggctctgg ggggctttng ggtgtncctc |
421 | tngggcaggt cctggctggc attggcct |
|
ACCESSION No. T51316 | |
ORIGIN |
1 | ttcatccgct gcatgtggaa aactggcccg atacctcgca ctacgagttt ctcgccgaca | |
61 | ctatgtggag cgattttgcc tacggtcgca atgccgtata cccggaagcn atcacggcaa |
121 | cgcanctngt cgcgttatcc cattgaacat tatgagaatc gcgatgtttc ggtcgatggt |
181 | gcggaaaagc gcggcntgct tcttacttgc cgcattgtgc cgccgattga ccgggaaaag |
241 | cgattcatgt tgatgttgcg tacatcttgg ggccttgcgt tgagggcgca ccgttcagg |
|
ACCESSION No. T72535 | |
ORIGIN |
1 | atgacctctg caaagagaag gtcagctata ngtagggaga aaaggaagaa ggcaagaaaa | |
61 | ggagactcga gatgagttta catccaagag aagcacagat gtttgtaatc tacctagaat |
121 | aatgtgaagt acctgtccag catgtatgct cagatcctcc attcattagc acaagctgaa |
181 | aacatgaact gcaaattcta caccagcatc ctttgcttcc tccatggcag tgggaggtag |
241 | caaggggagt ccaacacttc tccatgacgt angaaaggca gggaaaaata ctgnt |
|
ACCESSION No. W72103 | |
ORIGIN |
1 | gtttgtgaaa aggaacaaaa tgaanttgaa ttggacatgt gctttaagca ngccaacaga | |
61 | caacacacca ctagagacac acatcaaaag caatcacagt gctatgatca aatgatgggt |
121 | acatgtgaac acatc |
-
All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
-
All nucleotide and/or amino acid sequences associated with accession numbers referred to or cited herein are incorporated by reference in their entirety.
-
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.